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The Effects of a Structured Adherence Intervention to HAART on Adherence and
Treatment Response Outcomes
Donald E. Kurtyka
ABSTRACT
Background: Adherence to antiretroviral (ARV) medications in excess of 90-95%
is necessary for optimal response to suppress HIV replication and to maintain and/or
restore immune function. A number of interventions have been shown to improve ARV
adherence, but no research has been conducted which evaluates proactive monitoring of
pharmacy refill adherence and subsequent intervention when inadequate adherence is
identified.
Purpose: The purpose of this project was to compare treatment response,
pharmacy refill adherence and self-reported medication adherence between two groups of
patients: those participating in an AIDS Drug Assistance Program (ADAP) and those
participating in a Medicaid-funded medication access program. The ADAP served as a
structured adherence intervention (SAI) based on procedural and administrative processes
required by the state-managed program. Additionally, covariates that can impact
adherence were studied including utilization of adherence services and interventions and
factors related to HIV disease, antiretroviral agents and sociodemographic factors.
Method: This retrospective comparative study examined secondary data to assess
424 patients who received clinical and pharmacy services at one treatment site in 2005.

x

Analysis: Logistic regression was performed to test the effects of the SAI on
treatment response (CD4 and HIV RNA response), self-reported adherence, and
pharmacy refill adherence while controlling for the covariates.
Results: Patients participating in the SAI demonstrated higher levels of both selfreported and pharmacy refill adherence compared to patients receiving usual care.
Although patients participating in the SAI program demonstrated better virologic (HIV
RNA) responses to HAART compared to patients receiving usual care, immunologic
(CD4 lymphocyte) responses to HAART were not significantly different compared to
subjects in the usual care program.
Conclusion/Discussion: This study provides information on the effects of a
structured programmatic intervention on medication adherence and response to treatment
and will be used to inform policy decision making at the local and State level.
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CHAPTER ONE: INTRODUCTION
Background
Human immunodeficiency virus (HIV) infection was originally considered a
terminal illness when identified in the early 1980s. Nearly everyone who contracted the
disease advanced to Acquired Immunodeficiency Syndrome (AIDS) and death (Bartlett
& Gallant, 2005). Treatment with the first antiretroviral agent zidovudine (AZT), which
became available in the late 1980s, gave short-term encouragement to those with HIV
disease. Within a year, however, most persons no longer responded to this medication
and became ill or died. A breakthrough occurred in 1996 with the introduction of an
effective combination therapy capable of suppressing HIV replication. These potent
combination drug regimens now known as highly active antiretroviral therapy (HAART)
redefined HIV disease into a chronic illness requiring long-term management rather than
a terminal disease (Johnson et al., 2006). During the last decade, advances in the
scientific understanding of HIV dynamics and pathogenesis, the development and
widespread use of quantitative HIV ribonucleic acid (RNA) assays to quantify serum
levels of HIV, and the availability and use of powerful antiretroviral agents culminated in
dramatic changes in HIV clinical care and improved clinical outcomes (Williams et al.,
2006).
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Adherence
The World Health Organization (2003) broadly defined adherence as the extent to
which a patient's behavior, such as taking prescribed medications or following a diet,
corresponds with the interventions of the healthcare provider. Medication adherence in
HIV disease has been defined as the ability of the person living with HIV/AIDS to be
involved in choosing, starting, managing and maintaining a combination medication
regimen to control viral replication and improve immune function (Jani, 2002). The
terms adherence and nonadherence are meant to be nonjudgmental, statements of fact
rather than expressions of blame toward the patient or provider (Bangsberg, Perry et al.,
2001).
Highly Active Antiretroviral Therapy (HAART)
Antiretroviral (ARV) drugs for the treatment of HIV disease are broadly classified by
the phase of the HIV lifecycle that the drug inhibits. Antiretroviral drugs currently
licensed for clinical use by the Food and Drug Administration are classified as
nucleoside/nucleotide reverse transcriptase inhibitors (NRTI), non-nucleoside reverse
transcriptase inhibitors (NNRTI), protease inhibitors (PI), and entry inhibitors (EI). Table
1 lists these agents by classification and mechanism of action.
HAART is the combination of at least three ARV drugs that target at least two
different parts of the HIV lifecycle or stop the virus from entering CD4 lymphocytes. A
panel of experts convened by the Department of Health and Human Services regularly
publishes guidelines suggesting preferred and alternative combinations that can be
combined to form a HAART regimen. HAART typically includes two NRTIs paired
with an NNRTI or a PI. In advanced stages of HIV disease or when significant
2

medication resistance is present, HAART regimens may include more than four or five
agents (National Institutes of Health, 2006).

Table 1
FDA Approved Antiretroviral Agents
Classification
Nucleoside and nucleotide
reverse transcriptase inhibitors
(NRTI)

Mechanism of Action
The reverse transcription process is blocked.
HIV RNA cannot be converted to HIV DNA
and viral reproduction is terminated.

Agents
Zidovudine
Lamivudine
Stavudine
Entricitabine
Didanosine
Tenofovir
Abacavir

Non-nucleoside reverse
transcriptase inhibitors (NNRTI)

The reverse transcription process is blocked.
HIV RNA cannot be converted to HIV DNA
and viral reproduction is terminated.

Nevirapine
Efavirenz
Delavirdine

Protease inhibitors (PI)

Final viral assembly is inhibited when protease
enzymes are not available to reassemble viral
particles and produce new virus.

Saquinavir
Ritonavir
Nelfinavir
Indinavir
Lopinavir/ritonavir
Atazanavir
Fosamprenavir
Tipranavir
Darunavir

Entry Inhibitors

The process of HIV binding to a CD4
lymphocyte is interrupted, thus blocking the
ability of HIV to infect a CD4 lymphocyte.

Enfuvirtide
Maraviroc

Effects of HAART on Outcomes
The introduction of HAART has dramatically decreased morbidity and mortality
among HIV-infected patients throughout the developed world (Egger et al., 1997; Hogg
et al., 1998; Palella et al., 1998). In the United States, mortality from HIV infection
decreased by 70% between 1996 and 1998 and decreased an additional 14% between
1998 and 2002 (Centers for Disease Control, 2004; Frick, Tapia, Grant, Novotny, &
3

Kerzee, 2006; Hogg et al., 1998; Palella et al., 1998). The incidence of opportunistic
infections associated with AIDS has also decreased significantly with the use of HAART
(Grabar et al., 2000).
Patients’ ability to adhere to complex regimens is an essential component of
successful antiretroviral therapy (Kitahata et al., 2004) and is widely regarded as the most
important mutable determinant of clinical outcomes in the HIV-infected patient (Wood et
al., 2003). Although a decrease in the number of CD4 lymphocytes is the strongest
predictor of progression to AIDS and death, adherence to HAART is the second most
common predictor (Bangsberg, Perry et al., 2001; Garcia de Olalla et al., 2002; Hogg et
al., 2002; Machtinger & Bangsberg, 2006; Wood et al., 2004). In studying levels of
adherence, Bangsberg and his team (2001) found that no patients in a group of highly
adherent patients developed AIDS-defining events over the 16 months of the study
compared to those with moderate and low adherence. Each 10% difference in mean
adherence was found to be associated with a 28% reduction in risk of progression to
AIDS. Another group concluded that adherence behavior is a dynamic process and
continued adherence was associated with improved response to ARV therapy (Carrieri et
al., 2001). It has been estimated that a nonadherent patient receiving HAART is 3.87
times more likely to die than an adherent patient on the same therapy (Garcia de Olalla et
al., 2002).
Although adherence to HAART at a level above 95% has been associated with
optimal viral suppression, the relationship between various levels of adherence, resulting
virologic treatment responses, and long-term clinical outcomes has not been determined.
Previous studies have examined relatively small numbers of patients in relation to short4

term virologic response to HAART. Adherence to antiretroviral therapy in both the
short-term and the long-term is crucial for treatment success and must be continually
reinforced (Hammer et al., 2006).
Difficulty Adhering to HAART / Nonadherence
Overview and Implications
The Department of Health and Human Services (DHHS) develops and publishes
HIV treatment guidelines on a regular basis. These guidelines reinforce that one of the
most important issues in managing patients receiving HAART is adherence to therapy
(National Institutes of Health, 2006). When treating HIV disease, adherence levels need
to be at the 90-95% level to achieve and maintain therapeutic effectiveness (Murphy, Lu,
Martin, Hoffman, & Marelich, 2002; Paterson et al., 2000). Maintaining this threshold
can be complex and difficult. Adherence to HAART has been described as the
“Achilles’Heel” of antiretroviral therapy (Simoni, Frick, Pantalone, & Turner, 2003)
because of the difficulty associated with maintaining such high levels of medication
adherence.
There are a number of contributing factors that make 100% adherence to HAART
difficult for many patients including the complexity of the HAART regimen (multiple
pills, multiple doses, food requirements and restrictions), immediate and long-term side
effects associated with the ARV agents, and comorbid conditions such as active
substance abuse and mental illness.

5

Prevalence of Nonadherence
Nonadherence to medication therapy has been a problem for as long as remedies
for health conditions have been prescribed (Chesney, 2006). Evidence shows that poor
adherence to ARV regimens has serious consequences for HIV-infected patients including
failure to prevent viral replication, an increased likelihood of developing viral resistance,
decreasing CD4 lymphocyte counts, ineffective disease treatment, increasing illness,
advancement to AIDS, and ultimately death (Bangsberg, Hecht et al., 2001; Gifford et al.,
2000; Miller & Hays, 2000a; Murphy, Lu, Martin, Hoffman, & Marelich, 2002; Turner,
2002). Despite these risks, nonadherence to HAART is widespread in the United States
and in Europe with estimates of the percentage of prescribed doses taken ranging from
60% to 70% (Bangsberg et al., 2000; Bartlett, 2002; Gordillo, del Amo, Soriano, &
Gonzalez-Lahoz, 1999; Martin-Fernandez, Escobar-Rodriguez, Campo-Angora, &
Rubio-Garcia, 2001; Moatti et al., 2000; Nieuwkerk et al., 2001).
The average rate of adherence varies by the method used to assess it and the
group studied. In one prospective study, 140 individuals in a public U.S. hospital HIV
clinic were followed for one year after initiation of HAART. The investigators assessed
adherence using three methods and calculated a composite adherence rate of only 71%.
Only six percent of the patients took at least 95% of their medications, the optimal level
for durable virologic and clinical success (Golin et al., 2002). Studies of different groups
of HIV-positive individuals in the United States and abroad generally show similar,
suboptimal rates of adherence (Gordillo, del Amo, Soriano, & Gonzalez-Lahoz, 1999;
Knobel et al., 2001; Murri et al., 2000; Walsh, Mandalia, & Gazzard, 2002). Rates of
adherence are known to decline over time. Most patients taking HAART, regardless of
6

their background or life situation, will encounter difficulties with adherence at some point
(Howard et al., 2002; Mannheimer, Friedland, Matts, Child, & Chesney, 2002).
Inadequate adherence may eventually undermine the dramatic improvements in
HIV-related health parameters seen in resource-rich countries and the expected response
in developing countries as HAART becomes more widely available. Not only can
nonadherence negatively impact clinical outcomes, it can add significantly to the cost of
care. It was, however, the recognition that nonadherence results in transmittable forms of
drug resistant strains of HIV that brought attention to the problem rather than suboptimal
clinical outcomes (Chesney, 2006).
Although most experts accept that adherence to antiretroviral medication is
critical to the effectiveness of HIV treatment (Bangsberg et al., 2000; Haubrich et al.,
1999; Liu et al., 2001), few rigorously designed studies have documented the efficacy of
interventions to improve adherence to ARV treatment (Williams et al., 2006). While the
potency of current therapeutic options for treatment of HIV disease has decreased
morbidity and increased survival, imperfect adherence to HAART remains a major cause
of treatment failure among patients with HIV disease (McNabb et al., 2001) (Palella et
al., 1998; Paterson, Potoski, & Capitano, 2002).
Impact of Adherence
Highly active antiretroviral therapy has resulted in a longer life during the chronic
stage of HIV infection. The Swiss HIV cohort study initially documented this trend,
showing an increase in the survival rate from 19% in 1991 to 62% in 1996 (Egger et al.,
1997). Recent projections published in 2006 estimated that the life expectancy of
someone currently beginning care for treatment of HIV is at an all-time high of 24.2
7

years (Schackman et al., 2006). It is imperative that research be conducted to more fully
understand adherence and to identify evidence-based interventions that can be developed
and implemented to improve patient outcomes in people living with HIV disease.
Factors Associated with Nonadherence
Adherence to medication is a complex behavior which is influenced by many
factors related to the patient, the prescribed treatment, the disease state, the healthcare
provider and patient-healthcare provider relationship, and the healthcare system. Many
studies have yielded discordant results, making it difficult to achieve consensus on
modifiable barriers and predictors on which adherence intervention strategies should be
designed (Ammassari et al., 2002).

Some of these factors are immutable such as age,

income, literacy, and the patient's social milieu while other factors are potentially
alterable, such as depression, substance abuse, regimen complexity, medication side
effects, and the therapeutic relationship between patient and provider.
Patient Factors
Patient factors affecting adherence include the sociodemographic factors of age,
gender, race/ethnicity, income, education, literacy, housing status, insurance status, and
risk factor for acquisition of HIV infection. Psychosocial factors typically encompass
mental health issues, substance use, social climate and support, knowledge and attitudes
about HIV and its treatment). Additionally, patients have identified many diverse
reasons for missing their medications. Gifford and his colleagues (2000) found that
organizational difficulties (e.g., too busy, forgot, away from home, change in routine) and
emotional issues were the most common reasons for missed doses.

8

Conflicting results have been reported regarding the association between
sociodemographic factors and adherence behavior. When an association was found, the
direction was consistent: younger age, non-white race/ethnicity, lower income, lower
literacy, and unstable housing were negatively associated with adherence in resource-rich
settings. Gender, educational level, insurance status, and HIV risk factors generally were
not associated with adherence behavior (Altice, Mostashari, & Friedland, 2001; Gifford
et al., 2000; Golin, Isasi, Bontempi, & Eng, 2002; Haubrich et al., 1999; Holzemer et al.,
1999; Kleeberger et al., 2001; Mannheimer, Friedland, Matts, Child, & Chesney, 2002;
Paterson et al., 2000).
Psychosocial Factors
More consistent associations were found between certain psychosocial factors and
adherence behavior. Common predictors of less than adequate adherence include
untreated depression, other psychiatric morbidity such as anxiety and bipolar disease,
stressful life events and lack of social and family support (Ammassari et al., 2001; Cinti,
2000; Gordillo, del Amo, Soriano, & Gonzalez-Lahoz, 1999; Holzemer et al., 1999).
Active substance abuse including cocaine, marijuana, amphetamines, sedatives, and
moderate to heavy alcohol consumption have also been inversely linked to adherence
(Golin et al., 2002). Patients who are unable to correctly identify their drug regimen or
describe the relationship between adherence and drug resistance are also more likely to
be nonadherent. Belief in the efficacy of the medication and the presence of social
support systems has been positively related to adherence to HIV (Ammassari et al., 2002)
(Miller et al., 2003; Stone et al., 2001; Tucker, Burnam, Sherbourne, Kung, & Gifford,
2003).
9

Treatment Related Factors
Factors related to the treatment regimen can impact adherence including the
number of pills prescribed, complexity of the regimen including dosing frequency and
food instructions and restrictions, convenience of the regimen, type of ARV agents
prescribed (e.g. protease inhibitor vs. non-nucleoside reverse transcriptase-based), side
effects associated with the agents and the ability to incorporate the regimen into an
individual's daily routine (Bartlett, 2002; Chesney, 2000; Walsh, Mandalia, & Gazzard,
2002). In general, adherence declines with the emergence of side effects. Side effects
associated with HAART are common and include transient events such as diarrhea,
nausea and fatigue as well as longer-lasting adverse effects such as metabolic disorders
including diabetes and lipid disorders, lipodystrophy and neuropathy (Chesney, 2003).
With regards to HAART, side effects are the primary cause of nonadherence and account
for more regimen changes than do treatment failures (Ammassari et al., 2001).
The association between the number of doses per day and patient adherence is
well described, with adherence declining as dosing frequency increases (Bartlett,
DeMasi, Quinn, Moxham, & Rousseau, 2001; Claxton, Cramer, & Pierce, 2001). High
pill burden has been reported as a primary reason for missing or discontinuing HAART
(Bartlett, DeMasi, Quinn, Moxham, & Rousseau, 2001; Trotta et al., 2002). With the
continued development of newer antiretroviral treatment agents, attention has focused on
improving the efficacy, convenience and tolerability of medications with particular
emphasis placed on reducing pill burden and dosing frequency. Data are emerging that
demonstrate a positive association on adherence with once daily HAART regimens
(Johnson et al., 2006).
10

Bartlett (2001) identified pill burden as the most significant predictor of HAART
response. Since that time, treatment regimens have continually been simplified. In 2006,
a one-tablet, once-daily HAART regimen became available and greatly reduced the
scheduling requirements and pill burden associated with HAART (U.S. Food and Drug
Administration, 2006). In a meta-analysis of 23 clinical trials involving 3,257 patients to
determine predictors of virologic suppression, researchers found pill burden to be the
most significant predictor of antiretroviral response (Stone et al., 2001). Although oncedaily regimens demonstrated improved attainment of virologic control in two large RCTs
that compared once-daily with twice-daily regimens, it is not clear if the benefit seen with
once-daily HAART resulted from increased potency of the regimens studied, better
adherence, or both (Molina, Ferchal, & Rancinan, 2003) (Raffi, Saag, & Cahn, 2003;
Saag, Cahn, & Raffi, 2002). Data from additional studies related to this issue are
expected in the near future.
Stone et al. (2001) conducted a cross-sectional survey of women and found that
self-reported adherence was better among patients with less complex HAART regimens
due in part to the fact that patients’ understanding of regimen dosing decreases as
regimen complexity increases. Therefore, simplifying HAART regimens may have an
important role in improving patients’ adherence. Conversely, increasing complexity in
the medication regimen is associated with decreasing patient adherence.

11

Disease Characteristics
Disease characteristics affecting adherence include the stage and duration of HIV
infection, HIV-related symptoms and AIDS-associated opportunistic infections.
Adherence rates are consistently lower for a long term, chronic illnesses and for
asymptomatic conditions (Graney, Bunting, & Russell, 2003). Over time, even the most
motivated patients may find it increasingly difficult to remain adherent (Ickovics et al.,
2002).
Asymptomatic HIV-infected patients may be less adherent since the only
immediate perceived effect of HAART may be deterioration in health status and wellbeing as a result of medication side effects and disruptions in daily routine. Certain
patterns of behavior in patients with chronic, asymptomatic illness have been linked to
nonadherence including not filling prescriptions, forgetting doses, taking incorrect doses,
stopping medication too soon, and self-regulating the regimen to manage side effects
(Ammassari et al., 2002; Chesney, 2003; Hubbard, 2006; Trotta et al., 2002).
Conversely, Williams (1999) found that adherence is frequently greater in patients
with advanced HIV disease as the improvement in disease-related symptoms resulting
from controlling viral replication with HAART often outweighs the adverse effects of
treatment. Increased adherence was seen in patients with opportunistic infections. The
researchers believed this was explained by the patients’ desire for improved health and a
stronger motivation to adhere. Several studies described a relationship between HIVrelated symptoms and nonadherence (Holzemer et al., 1999; Wagner, 2002).
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Holzemer and colleagues (1999) found that clients with higher symptom scores,
particularly depression, were more likely to be nonadherent to medication, not to follow
provider advice, and to miss appointments while those who reported having a meaningful
life, feeling comfortable and well cared for, using their time wisely, and taking time for
important things were both more adherent to their medications and more likely to follow
provider's advice. They suggested that strategies to enhance adherence should include
recognition and treatment of symptoms (particularly depression) and an understanding of
clients' perceptions of their environment.
Patient-Provider Relationship and Social Support
Several studies have documented that positive relationships with friends, family
and healthcare providers can impact adherence to medication. Researchers found that a
positive patient-provider relationship can be an important motivating factor for taking and
adhering to HAART. Factors that have been identified as strengthening patient-provider
relationships include communication quality and clarity, compassion, willingness to
include patients in treatment decisions, adequacy of referrals, and convenience of visiting
the provider. Conversely, frustration for providers has been associated with lack of
adherence to treatment, missed appointments, complexity of treatment regimens and
medication side effects (Ammassari et al., 2002; Chesney, 2000).
Health beliefs, coping skills and rapport with healthcare providers have been
correlated with adherence to HAART. Patients are more likely to be adherent if they
have confidence in, and guidance from, their healthcare providers (Bertholon, Rossert, &
Korsia, 1999; Holstad, Pace, De, & Ura, 2006). The patient's overall satisfaction and
13

trust in the provider and clinical staff along with the patient's opinion of the provider's
competence, willingness to include the patient in the decision-making processes, the
adequacy of referrals and the convenience of visiting the provider can affect adherence
(Ammassari et al., 2002; Chesney, 2000; Stone et al., 1998).
Findings from two studies suggested an association between stressful life events
and nonadherence (Gifford et al., 2000; Moatti et al., 2000). Lack of social or family
support and poor self-efficacy have also been found to be an important risk factor for
nonadherence (Altice, Mostashari, & Friedland, 2001; Catz, Kelly, Bogart, Benotsch, &
McAuliffe, 2000; Gordillo, del Amo, Soriano, & Gonzalez-Lahoz, 1999; Murri et al.,
2002; Stone et al., 1998). Ammassari and colleagues (2002) concluded that the presence
of tangible and emotional support can reduce barriers and increase motivation for
adherence.
Lucas et al. (2004) found that patients who kept medical appointments were more
likely to be adherent to medication. Additionally these researchers found that adherence
was associated with patients’ understanding that suboptimal adherence leads to resistance
and a recognition that taking all medication doses is critically associated with adherence.
It has been suggested that members of the healthcare team work in partnership with
patients and to involve representatives from the entire HIV community to strengthen
collaborative efforts related to the promotion of adherence (Chesney, 2000).
Environmental Factors: The Healthcare System
Research addressing the relationship between the healthcare setting and adherence
behavior are limited. Chesney (2000) found that aspects of the clinical setting can
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positively impact adherence such as easy access to ongoing primary care and
convenience in scheduling appointments, involvement in a dedicated adherence program,
availability of transportation and child care services, comfort with the clinical
environment, perceived confidentiality, and satisfaction with past experiences in the
healthcare system. Conversely, dissatisfaction with experience in the healthcare system
has been associated with nonadherence. Women studied by Powell-Cope and colleagues
(2003) identified difficulty obtaining medication refills and concerns related to
confidentiality as barriers to adherence.
Conclusions
Adherence to highly active antiretroviral therapy is strongly correlated with both
immunologic and virologic success, as evidenced by decreased HIV RNA levels and
increased CD4 lymphocyte counts. Unfortunately, achieving and maintaining high levels
of adherence to complex HAART regimens can be very difficult (Bangsberg et al., 2000;
Haubrich et al., 1999). The reasons for inadequate adherence are complicated and often
involve many variables related to the medications, co-morbid health conditions,
environmental barriers and psychosocial concerns. Consequently, successful HAART is
often limited due to inadequate medication adherence (Carpenter, 1997; Knobel et al.,
2001).
Experts in the field of HIV have come to consensus on the importance of adequate
adherence to HAART (Bangsberg & Deeks, 2002) (Chesney, 2003; Paterson et al.,
2000). Despite the importance of this subject, empiric research on adherence
interventions for HIV-infected individuals is minimal. Simoni and colleagues (2003)
described adherence research as being in the embryonic stage. In their 2004 adherence
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supplement, the DHHS guidelines concluded that interventions to improve adherence for
HAART are insufficiently characterized and understood, and additional research
regarding the topic needed (National Institutes of Health, 2004). Berg and Arnsten
stressed that adherence measurement is needed in clinical and research settings, and
called for research to evaluate methods and provide recommendations for research and
clinical care (Berg & Arnsten, 2006).
The importance of adherence is demonstrated by the integration of adherence
recommendations into national consensus guidelines for the use of HAART antiretroviral
therapy (National Institutes of Health, 2006). While more adherence research is called
for, methodological barriers are evident. Uncertainty exists regarding the best measure of
adherence in both clinical practice and in research settings. Patient report, pill counts,
and provider estimates may overestimate adherence, while electronic methods such as the
Medication Event Monitoring System (MEMS) frequently underestimate ARV
adherence, are too costly, and are not practical for use in routine clinical care.
Furthermore, the process of monitoring patients behavior when measuring adherence may
act as an intervention that changes adherence (Turner & Hecht, 2001).
Statement of the Problem
Adherence to HAART has arisen as one of the most important issues in the
effective treatment of HIV disease. The difference in long-term viral suppressive
response between those who take their medicine correctly 90-95% of the time and those
who do not, can be the difference between life and death (Paterson et al., 2000).

The

identification of effective and clinically practical adherence interventions could greatly
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improve the response to treatment modalities. For this reason, it is critical to determine
interventions that promote adherence.
Purpose of the Study
The purpose of this retrospective comparative study was to evaluate the effects of
a structured adherence intervention (SAI) as a component of an existing antiretroviral
access program on adherence to HAART and response to treatment as compared to usual
care. In the structured adherence intervention providers closely monitored monthly HIV
medication refills and provided structured adherence intervention when indicated.
Patients receiving usual care were enrolled in a Medicaid-funded medication access
program and did not receive ongoing medication refill monitoring and structured
adherence intervention. Both patient groups received their ARV medications and
outpatient HIV medical care from a single treatment center and pharmacy.
Specific Study Aims and Research Questions
Study Aim 1: To determine whether patients participating in the SAI program
experienced higher levels of adherence compared to patients receiving usual care,
controlling for adherence services and intervention, HIV disease-specific factors, ARVspecific factors, and sociodemographic factors.
Research questions:
1a.

Is there a difference in self-reported adherence in subjects participating in
the SAI program compared to those who receive usual care?

1b.

Is there a difference in pharmacy refill adherence in subjects participating
in the SAI program compared to those who receive usual care?
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Study Aim 2: To determine whether patients participating in the SAI program
experienced improved response to treatment compared to patients receiving usual care,
controlling for HIV disease-specific factors, ARV-specific factors, and sociodemographic
factors.
Research questions:
2a.

Is there a difference in CD4 lymphocyte response in subjects participating
in the SAI program compared to those who receive usual care?

2b.

Is there a difference in HIV RNA response in subjects participating in the
SAI program compared to those who receive usual care?
Hypotheses

1.

Patients participating in the SAI will have higher levels of self-reported and
pharmacy refill adherence compared to patients receiving usual care, controlling
for covariates.

2.

Patients participating in the SAI program will have better immunologic (CD4
lymphocyte) and virologic (HIV RNA) responses to HAART compared to those
receiving usual care, controlling for covariates.
Significance of the Study
Although a great deal of progress has been made in the measurement of

medication adherence in HIV disease and evaluation of adherence interventions,
additional work is still needed. Ongoing research is needed to develop and validate
accurate, practical and cost-effective methods for measuring adherence to HAART that
can be used in both developing and industrialized countries. Study samples should
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include more racial and ethnic minorities and women to more accurately represent the
current population with HIV disease.
Despite the importance of adherence related to HAART, empiric research on
adherence interventions for HIV-infected individuals is minimal. Although several
researchers have studied self-reported and pharmacy refill adherence, there are no
published studies of medication access programs that proactively monitor pharmacy
refills and initiate adherence interventions when adherence deficiencies are identified.
This study is designed to further the existing knowledge with relation to these additional
variables. The findings will provide information on the effects of a programmatic
intervention on medication adherence and response to treatment that can be used to
inform policy decision making at the local, regional, and state levels.
Summary
This chapter presented the importance of adherence related to HAART and the
need to identify effective interventions to foster adherence. High levels of adherence to
HAART are necessary for optimal response to therapy. Optimal response to HAART
results in improved viral suppression, improved immunologic response and functioning,
and ultimately a decrease in morbidity and mortality. Nonadherence remains strongly
associated with mortality (Wood et al., 2003). Limited research studies have identified
effective interventions which can improve adherence.
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CHAPTER TWO: REVIEW OF THE LITERATURE
Introduction
This chapter includes a review of research related to the measurement of
adherence to HAART in HIV disease and interventions to increase or strengthen
adherence to HAART. Although adherence to HAART is the strongest predictor of HIV
viral suppression, drug resistance, disease progression and death in HIV-infected
individuals, there is no standard approach to adherence assessment and intervention in
routine clinical practice.
Definition of Adherence
HAART adherence researchers have yet to identify a standardized definition of
adherence and few studies use consistent measures of adherence. Therefore adherence
data must be interpreted with caution and comparison among studies is difficult (Hill,
Kendall, & Fernandez, 2003; Powell-Cope, Toney, & Montano, 2001). One study may
define adherence as the percentage of prescribed doses taken within two hours of
scheduled dosing time over a 1-week period according to electronic data monitoring
(EDM) while another may operationalize adherence as the percentage of prescribed doses
taken in the last month according to self-report. Adherence studies are also inconsistent
with regard to measurement of clinical outcomes. Some studies reported immunologic
effects in terms of CD4 lymphocyte response while others reported virologic outcomes in
terms of HIV RNA response. Some studies reported both immunologic and virologic
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outcomes while others do not address either of these outcome measurements (Simoni,
Pantalone, Frick, & Turner, 2005). Holzemer et al. (1999) even expanded the concept of
adherence beyond only medication adherence to include following clinician instructions
and missed appointments.
Measurement of Adherence
Adherence to HAART is a complex issue involving social, cultural, economic and
personal factors. This complexity makes it difficult to identify a reliable and valid single
measure of adherence that is appropriate for all settings (Chesney, 2006). Research and
clinical care have also been hindered by the lack of an inexpensive, quick and accurate
method to measure adherence (Dunbar-Jacob & Mortimer-Stephens, 2001).
Chesney (2006) argued that it may be impossible to develop a “gold standard” definition
of adherence and a standard measurement of adherence as the HIV epidemic is too
diverse throughout the globe.
Introduction
Clinical studies employ a number of methods, alone or in combination, to
measure medication adherence. A number of studies have shown, however, that the
objective measures used in research, although impractical for most clinical settings, are
more sensitive than patient self-report for detecting medication adherence (Machtinger &
Bangsberg, 2006).
Adherence is usually measured as either a categorical or continuous variable.
Two common approaches to defining a categorical outcome are to consider whether the
patient missed any pills over a specific interval (such as the last 3 or 7 days) or whether
the patient has exceeded a set percentage of doses taken (usually 95%). This simplistic
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dichotomous classification may not capture the complexity of adherence patterns such as
adhering to timing of medication doses, medication-specific food requirements and
taking the correct number of pills (Chesney, 2003).
Measuring adherence as a continuous variable is less common in the literature
than a dichotomous measure. When measured as a continuous variable, adherence is
usually defined as the proportion of prescribed doses taken as measured by an electronic
drug monitoring device, self-report, or pill count. Adherence can also be measured as a
continuous variable by obtaining the percentage of pills available for consumption by
pharmacy refill records or the number of missed doses over a specified time period
(Simoni, Pantalone, Frick, & Turner, 2005). Many published studies simply reported the
criterion for adherence as meeting the minimum level of drug consumption such as
greater than 70, 80, or 90% (Fogarty et al., 2002).
Adherence measurement is frequently classified as subjective (in the opinion of
the patient) or objective (data recorded independently of the patient) (Orrell, 2005).
Subjective approaches include self-report and self-administered questionnaires in which
patients are asked to report the number of medications missed or taken based within a
designated time frame. Objective methods include electronic data monitoring (EDM)
devices, pill counts and pharmacy refill data. These various methods of measuring
adherence will each be explored.
Subjective Measures of Adherence
Patient Self-Report
Patient self-report offers a relatively inexpensive, simple and non-intrusive means
of incorporating adherence data into routine clinical practice and the research setting.
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Self-report is useful due to the relatively low cost, ease of administration and flexibility
of use in a variety of settings (Bangsberg, Bronstone, Chesney, & Hecht, 2002).
Although self-report is one of the most common methods of assessing medication
adherence, inaccuracy may result due to imprecise or inconsistent questioning, patient
forgetfulness and poor recall, or the patient’s desire to provide socially desirable
responses along with a desire to please the healthcare provider and prevent criticism.
Recall periods are inconsistent between studies (e.g. number of doses missed over the last
3 days vs. the number of doses missed over the last 30 days). Consequently, when selfreporting methods are used to assess adherence, levels are frequently over-estimated.
Although patients who admitted they have less than optimal adherence are almost
always truthful, the reverse is not always true (Miller & Hays, 2000b). Self-reported
adherence was over-reported when compared to adherence measured by EDM in a study
of 44 patients conducted by Melbourne and colleagues (1999). Using an investigatordesigned questionnaire, patients self-reported an extraordinary amount of perfect
adherence. Using EDM data, patients under-reported their degree of deviation from their
stated dosing times.
A benefit of self-reported adherence measurement is the potential to reveal the
reasons for missed or mistimed doses. Considering that clinical, behavioral and
psychosocial factors are among the most important factors that influence adherence
(Chesney, 2003), self-report provides an opportunity to identify factors that might
negatively affect adherence (Powell-Cope, Toney, & Montano, 2001).
Researchers conducted a meta-analysis and found that self-reported measures
reliably predicted clinical outcomes associated with adherence (Nieuwkerk & Oort,
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2005). This information is consistent with earlier studies that examined the relationship
between self-reported adherence and virologic outcomes, protease-inhibitor drug levels
and other clinical outcomes (Kerr, Walsh, Lloyd-Smith, & Wood, 2005). While patientreported adherence has been consistently associated with viral suppression, as has
adherence measured by EDM and unannounced pill count, self-reported adherence
questionnaires or interviews used in research may fail to identify 20% to 28% of
nonadherent patients (Bangsberg, Bronstone, & Hofmann, 2002).
A number of studies have demonstrated a positive association between selfreported adherence and HIV RNA suggesting that self-reports may be a valid indicator of
adherence (Haubrich et al., 1999; Montaner et al., 1998). Mannheimer and colleagues
(2002) prospectively studied the correlation between self-reported adherence and
successful response to HAART and found that a higher level of self-reported adherence
over time was associated with better immunologic and virologic outcomes. While
researchers concluded that self-reported medication adherence was a strong and
independent predictor of virologic outcome, they also indicated that other methods of
measuring adherence, such as the use of EDM, may allow for greater precision in
measurement. A recent meta-analysis confirmed that despite significant study
heterogeneity, the pooled association between self-reported HAART adherence and HIV
RNA was statistically significant (Nieuwkerk & Oort, 2005).
The manner in which clinicians and researchers communicate with patients
regarding adherence may impact the patient’s response. Patients may provide more
truthful information if the person collecting the data is not a direct member of the health
care team or if the patient believes the data will not be reported to clinicians (Orrell,
24

2005). Questioning, whether verbal or in writing, that is carefully structured,
nonjudgmental, culturally appropriate, and posed in a nonjudgmental manner and with
the use of permissive language may elicit the most accurate and truthful self-report data
(Mannheimer, Friedland, Matts, Child, & Chesney, 2002). An example might include:
“Patients with complex medication schedules like yours often miss doses of their
medications from time to time. Can you tell me how many doses you missed in the last
week?” An alternative might include: “Of the seven doses of medication you were
prescribed to take last week, how many did you actually take?” (Melbourne et al., 1999).
Patient self-report measures in the form of personal interviews or written
questionnaires have many advantages including low cost, minimal participant burden,
easy speed of administration, flexibility in terms of mode of administration and timing of
assessment, and the potential to yield specific information about the timing of doses and
adherence to food requirements. The specificity of self-report measures is high, i.e.,
patients’ acknowledgment of nonadherence is generally credible (Bangsberg, Hecht et al.,
2001). Self-report may not be feasible with some individuals such as the cognitively
impaired (Simoni et al., 2006).
Written medication diaries may increase the accuracy of self-report in patients
who have difficulty remembering their pill-taking history. A benefit is the relative low
cost associated with this method. However, one study suggested that patients did not
consistently complete diaries and when they did, they tended to fill in the information
immediately before a clinic visit. In one study utilizing diaries, only 25% of patients
returned their diaries as instructed (Miller & Hays, 2000b). Several other methods have
been used to obtain self-report adherence levels including computer-assisted self25

interviews, visual analog scales, self-report instruments and questionnaires, and clinical
assessment. Each will be briefly discussed.
Computer-Assisted Self-Interview
Computer-assisted self-interview (CASI) technology may be an efficient way of
obtaining self-reported data to identify HAART regimen errors and to monitor adherence.
CASI involves a computerized interactive structured interview that assesses patients'
understanding of HIV medication regimens and adherence levels. To minimize literacy
requirements, patients can listen to an audio track which reads the interview text that
normally would be presented visually on the computer screen. Photographs or graphics,
rather than antiretroviral names alone, can be used to facilitate visual recognition of a
patient's HAART regimen. If performed in conjunction with a clinician appointment, the
CASI data can be used to provide valuable teaching information as well as an assessment
of adherence (Bangsberg, Bronstone, Chesney, & Hecht, 2002).
CASI is time-efficient and may help detect nonadherence due to regimen errors or
missed doses. In one study, CASI adherence assessment identified serious HAART
regimen errors in up to 54% of patients. CASI-based adherence assessment can facilitate
intervention by alerting clinicians to potential adherence problems, prompting a more
detailed discussion of adherence during a clinical visit (Bangsberg, Bronstone, Chesney,
& Hecht, 2002). An adherence CASI has several additional advantages over traditional
self-report methods. Patients can be routinely and periodically assessed with a visual
query of their understanding of, and adherence to, their HAART regimen with minimal
use of clinician time. This may help to identify patients with regimen errors or in need of
focused or intense adherence intervention. Although there are expenses associated with
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initial start-up of this method, ongoing expenses are typically minimal. Web-based CASI
adherence assessment can be performed to identify difficulties with adherence more
rapidly than otherwise possible with assessments that are only performed during actual
clinic encounters.
Visual Analog Scale
Kalichman and his team (2005) used a pictographic visual analogue scale (VAS)
to assess medication self-efficacy in a low-literacy population and found that the scores
were associated with behavioral measures of medication adherence and HIV RNA
response. Visual analogue scales may be appropriate for patients with language
challenges as well as those with reading limitations. Giordano and his team (2004)
compared an investigator-administered VAS in conjunction with a more complicated 3day medication recall instrument and unannounced pill counts in a group of marginally
housed indigent patients who were on stable HAART regimens. The VAS demonstrated
good validity compared to unannounced pill count and HIV RNA, performed as well as
the 3-day recall instrument and was easier to administer and answer than other recall
instruments.
The VAS method offers several advantages over the traditional recall method
including decreased time requirement, ability to obtain data over a longer time frame and
a lower response burden on the patient (Giordano, Guzman, Clark, Charlebois, &
Bangsberg, 2004). Researchers compared the accuracy of patient recall of adherence
over 1, 3, 7, and 30-day intervals. Although it was expected that shorter periods of time
would result in the most accurate recall, researchers found that the 30-day VAS

27

performed slightly better than other measures of self-reported adherence over shorter
periods of time (Bangsberg, Bronstone, & Hofmann, 2002).
Self-Report Instruments and Questionnaires
Several adherence measurement instruments have been reported in the literature
primarily in the context of clinical research trials. Most adherence questionnaires ask
patients to recall the specific number of missed medication doses over a certain time
period such as the last 2-7 days. Patients are typically asked to recall day-by-day and
medication-by-medication doses or missed doses. Table 2 summaries adherence selfreport instruments.
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Table 2
Adherence Measurement Instruments
Instrument
Adult AIDS Clinical Trial
Group (AACTG) Adherence
Baseline Questionnaire
(Chesney et al., 2000)

Description

Population Studied

Reliability/Validity

9-page self-report of beliefs about
medications, social support,
missed or late doses, selfefficacy, psychological distress,
health habits, alcohol and drug
use, sociodemographic
characteristics and a 20-item
symptom index. Takes
approximately 10 minutes to
complete. Approximately 62
items.
6-page self-report of missed or
late doses, medication doses,
food requirements or special
instructions, reasons why doses
were missed and a 20-item
symptom index. Approximately
47 items.

HIV infected patients,
20% female, 30 nonwhite

Community Programs for
Clinical Research on AIDS
(CPCRA) Antiretroviral
Medication Self-Report (Form
646) (Mannheimer, Friedland,
Matts, Child, & Chesney,
2002)

7 day global recall of amount of
each medication taken (all, most,
about half, very few, none).
Number of items varies based on
number of ARV agents. Includs
checklist of 10 possible reasons
why ARV doses were missed.

HIV infected patients,
20% female, 72% nonwhite.

Not reported.

Godin’s Self-Reported
Questionnaire Assessing
Adherence to Antiretroviral
Mediation (Godin, Gagne, &
Naccache, 2003)

9 main questions of which 3
address nonadherence.
Developed in French and
English.

Predominantly HIV
infected men who have
sex with men

Not reported, although authors
stated, “adequate psychometric
properties” (Godin et al, 2003,
page 329)

Morisky Medication
Adherence Scale (MMAS)
(Corless et al., 2005; Morisky,
Green, & Levine, 1986)

4 brief yes or no questions that
address barriers to medicationtaking and permit the clinician to
reinforce positive adherence
behaviors

Limited use in HIV
disease; primarily
studied in patients with
hypertension, asthma
and hyperlipidemia

Internal consistency, α = 0.61 0.65

Patient Medication Adherence
Questionnaire Version 1.0
(PMAQ-V1.0) (DeMasi et al.,
2001)

6 items assess medication-taking
behaviors; 25 items assess
barriers and motivators to taking
medication

HIV infected patients,
85% male, 32% nonwhite.

Internal consistency, α = 0.79

Pictographic Medication SelfEfficacy Scale (Kalichman et
al., 2005)

Pictographic and color visual
analogue scale for assessing selfefficacy for medication
adherence. Uses 6 scenarios.

HIV infected patients,
36% women, 99%
African-American

Internally consistent (α = 0.68);
stability (2-week test/retest r =
0.63); evidence for convergent
and divergent construct validity.

Simplified Medication
Adherence Questionnaire
(SMAQ) (Knobel et al., 2002)

6 items based on Morisky scale

HIV infected patients,
72% male, 65% IDU

72% sensitivity; 91% specificity;
likelihood ratio of 7.94 to
identify nonadherent patients,
compared with MEMS; Internal
consistency, α = 0.75; Interobserver agreement 88.2%,
kappa 0.74.

Adult AIDS Clinical Trial
Group (AACTG) Adherence
Follow Up Questionnaire
(Chesney et al., 2000)

HIV infected patients,
20% female, 30 nonwhite
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No detailed information
available. Authors believe the
instruments “appear to be
practical, acceptable to patients”
and investigators and should
prove useful for efficient
collection of data describing
adherence to medications within
clinical trials populations.”
Highly significant association
was seen between self-report of
missed doses and detectable
viremia. Several correlates of
non-adherence were identified.

The Adult AIDS Clinical Trial Group (AACTG) developed both a baseline and a
follow-up self-report adherence assessment instrument for use in clinical trials. These
instruments have been included in a number of AACTG clinical trials to date and have
been widely disseminated to investigators both in the United States and abroad (Chesney
et al., 2000). The Community Programs for Clinical Research on AIDS (CPCRA) 7-day
global recall adherence questionnaire produced adherence data that predicted biologic
outcomes including HIV RNA and CD4 lymphocyte count. Adherence was associated
with non-detectable HIV RNA levels, a change in HIV RNA levels and a change in CD4
lymphocyte counts over a 12 month period (Mannheimer, Friedland, Matts, Child, &
Chesney, 2002).
Morisky, Green and Levine (1986) developed an instrument to assess adherence
to hypertension therapy which also addresses barriers to medication-taking. This tool has
been incorporated into several studies involving HIV-infected patients and demonstrated
success within this population (Corless et al., 2005; Gao & Nau, 2000). Knobel et al.
(2002) developed the Simplified Medication Adherence Questionnaire (SMAQ) to
identify non-adherent patients and determined the instrument to be adequate in most
clinical settings. The Patient Medication Adherence Questionnaire (PMAQ) assesses
medication-taking behaviors and barriers to adherence with HAART. Self-reported
adherence derived from this instrument predicted virologic outcomes but the authors
suggested additional refinement of the dimensions is needed (Boyle, 2003; DeMasi et al.,
2001).
Some researchers have either developed their own assessment tools or have
modified versions of other instruments, thus complicating the ability to compare data
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from different studies. Gau and Nau (2000) measured adherence using a Morisky-type
scale and two other measures of self-reported adherence to evaluate accordance yet found
discordant results. They recommend caution when comparing adherence rates between
studies that use different methods for assessing adherence.
Using self-report, Hill et al. (2003) studied patients’ definitions of adherence,
beliefs about consequences of nonadherence and reasons for current and past adherence
behavior. They identified three categories of adherence: 1) consistent adherers; 2)
currently adhering but with prior nonadherence; and 3) currently not adhering. They also
identified nine patterns of adherence: 1) takes medication very rarely; 2) alternates
between long period of taking and not taking medication; 3) skips entire days; 4) skips
doses; 5) skips one type of medication; 6) takes medication late; 7) does not stick to food
requirements or restrictions; 8) adheres to a purposely modified regimen and 9) adheres
to an unknowingly incorrect regimen. Noting that patients have definitions of adherence
that may be quite different from the definitions used by clinicians, they suggested that
adherence questionnaires and assessment tools need to reflect the diversity of patient
beliefs and patterns of medication-taking to more accurately measure adherence or less
than optimal adherence.
In a large meta-analysis Simoni and colleagues (2006) observed a robust pattern
of association between self-reported adherence and HIV RNA. In 84% of recall periods,
self-reported adherence was associated with HIV RNA based on odds ratios or simple
measures of correlation. The association was statistically significant across a variety of
self-reported measures, administration modalities, and recall periods. These findings are
consistent with the conclusions of a meta-analysis of adherence studies performed by
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Nieukerk and Oort (2005). The association between self-report and CD4 cell count was
less consistent, a finding that was not entirely unexpected since HIV RNA and CD4
count generally correlate, but discordant results are common. They concluded that even
brief self-report measures of HAART adherence can be robust.
Clinician Assessment
Studies examining healthcare provider abilities to predict their patients’ adherence
have been inaccurate and overly optimistic leading to the misidentification of
nonadherent patients (Bangsberg, Hecht et al., 2001; Haubrich et al., 1999). Paterson
(2000) found that physicians predicted adherence incorrectly for 41% of patients
compared with nurses who predicted it incorrectly for 30% of patients.
Miller and colleagues (2002) found that clinicians overestimated medication
adherence by almost 9% and inadequately detected poor adherence. Consequently,
clinicians missed opportunities to intervene with appropriate adherence interventions.
Miller and Hays (2000b) suggested that clinicians’ subjective assessment of adherence
may be as problematic as a patient’s self-reported adherence. HIV care providers in
routine clinical practice rarely predicted patient adherence. This often means that when
health care providers do not use patient reports of adherence, they are leaving the most
critical determinant of HIV treatment outcome to chance (Bangsberg, 2006).
Objective Measures of Adherence
In contrast to subjective measures, objective measures rely on data recorded
independently of the patient (Orrell, 2005). The following objective measurement
methods will each be reviewed: directly observed therapy, therapeutic drug monitoring,
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biomedical examination, pill counts, electronic monitoring devices, and pharmacy refill
data.
Directly Observed Therapy
One way of assessing adherence is participation in directly observed therapy
(DOT) in which administration of each dose is directly monitored. DOT has been used in
the treatment of tuberculosis for decades and was later applied to HIV treatment (Mitty,
Stone, Sands, Macalino, & Flanigan, 2002). The first randomized controlled trial of
community-based DOT in HIV care revealed significantly higher levels of self-reported
adherence, higher CD4 lymphocyte response, and greater HIV RNA reduction than those
not participating in DOT (Altice, Mezger, & Bruce, 2003). DOT programs, often
modeled after those used in tuberculosis treatment programs, may not be practical in HIV
care due to the large and growing numbers of HIV-infected patients since these programs
are labor intensive, expensive and can be perceived as intrusive (Liechty & Bangsberg,
2003). While DOT may be more feasible with the increasing number of once a day
HAART regimens, many of these daily regimens are administered at bedtime which
increases the impracticality of DOT for this group of patients.
Therapeutic Drug Monitoring (TDM)
Monitoring of plasma and urinary drug levels has been proposed in clinical and
research settings. Serum levels of some drug metabolites provide evidence that
individuals are taking medication but they do not provide specific information about the
number of doses missed or taken, individual patterns of missed doses, or adherence to a
medication based on a time schedule. This method is prone to wide individual variation
in drug pharmacokinetics related to the properties of drugs, drug-drug interactions and
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variations in drug absorption. Moreover, drug levels may only reflect recently taken
medication doses rather than long-term patterns of drug levels (Miller & Hays, 2000a).
Low drug levels have been associated with self-reported nonadherence and virologic
failure (Murri et al., 2000; Nieuwkerk et al., 2001). TDM also is limited by a lack of
technologic standardization of assays as well as limited general availability of the
laboratory assays (Acosta & Gerber, 2002).
Some researchers have attempted to exploit the biologic changes induced by
antiretroviral agents to indirectly measure adherence. Stavudine and zidovudine can raise
the mean corpuscular volume, didanosine can alter uric acid levels and both indinavir and
atazanavir can increase bilirubin levels. While these data provide some degree of
objective measurement, they are only marginally sensitive and specific markers of
medication adherence and provide little information about individual patterns of missed
doses (Cinti, 2000; Miller & Hays, 2000a).
Biomedical Examination
Laboratory measurement of CD4 lymphocytes and HIV RNA levels has been
used as indirect measures of adherence. Wood and his colleagues (2004) determined that
adherence was the strongest independent predictor of an increase in CD4 lymphocyte
count after beginning HAART therapy. Unfortunately, biomedical markers including
CD4 lymphocyte cell counts and HIV RNA levels do not always correlate with adherence
levels. Patients can have a drug-sensitive virus and be adherent to their HAART regimen
yet still experience HAART failure due to the development of drug-resistant HIV strains,
drug interactions and unfavorable pharmacokinetic properties (Miller & Chang, 2002).
Additionally, laboratory testing can be expensive. Laboratory measures may be
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considered more useful when used in combination with other adherence measures such as
pill counts, self-report assessments and EDM (Cinti, 2000).
Pill Counts
Pill counts frequently are used in conjunction with clinical drug trials and provide
an objective means of assessing the number of pills removed from the bottles. Pill
counts are easy and inexpensive to perform (Miller & Hays, 2000b). Disadvantages of
pill counts are that they can be time consuming for clinical and research staff; they do not
guarantee that the pills were taken as prescribed; patients may knowingly empty the
bottle prior to the visit in anticipation of a pill count; they may forget to bring bottles to
the clinical site; and some may perceive pill counts as intrusive (Berg & Arnsten, 2006).
Unannounced pill counts may provide a more accurate assessment of adherence
rates than self-report. In one study this method was more predictive of HIV RNA than
self-reported adherence measures and performed well compared to electronic data
monitoring using computerized medication caps (Bangsberg et al., 2000). Unannounced
pill counts may not be practical in many settings since home visits are usually required.
Electronic Monitoring Devices
Computer-assisted electronic drug monitoring devices, also commonly referred to
as electronic data (and sometimes drug) monitoring (EDM) devices, are frequently used
in research settings and to a lesser extent clinical settings. Small electronic chips
embedded in the caps of pill bottles record each time a bottle is opened or closed and the
length of time the bottle is open. Data is downloaded to a personal computer periodically
for analysis. One of the more common EDM products is the Medication Event
Monitoring System (MEMS) (New York State Department of Health, 2001).
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Data collected from EDM equipment has been found to correlate highly with
concurrent HIV RNA (Samet, Sullivan, Traphagen, & Ickovics, 2001). Limitations
related to EDM include expense and the possibility of under-reporting adherence in
patients who elect to remove more than one dose at a time. Under-reporting may occur
when patients remove medication to fill a pill box or remove extra doses in planning to be
away from home for an extended period of time. EDM also assumes that the patient
actually takes each removed pill. Over-reporting can also occur as pills may be removed
but not swallowed and bottles may be opened without removing pills. EDM methods
have additional drawbacks including inconvenience, patient dissatisfaction and
confidentiality concerns (Mannheimer, Friedland, Matts, Child, & Chesney, 2002). EDM
is rarely used in clinical practice due to the expense of the equipment.
Pharmacy Refill Monitoring
Pharmacy refill data can serve as an adherence measure by providing the dates on
which antiretroviral medications were dispensed. This measure is based on a
straightforward premise that when a patient does not receive timely refills of a drug from
the pharmacy, he or she is either not taking medication between refills or is missing doses
such that a given prescription lasts longer than it should (Turner, 2002). Researchers have
studied the number of prescriptions picked up, timeliness of medication pickup and gaps
in medication based on refill data. These measures are usually calculated based on the
number of days’ supply obtained divided by the total number of days in the period or the
number of refills obtained divided by the expected number of refills over a given time
period (Steiner & Prochazka, 1997). Low-Beer, Yip, O’Shaughnessy, Hogg and
Montaner (2000) examined pharmacy dispensing data and found a significant linear trend
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in viral suppression across ordered categories of adherence. Pharmacy refill adherence
rates of 95% or greater were associated with high virologic success; success rates
decreased sharply with decreasing levels of adherence to refills.
Several studies have used pharmacy data to assess adherence among patients with
HIV disease. One study found that self-reported HAART adherence correlated with
pharmacy dispensing records and predicted viral suppression at levels > 97% (Fairley,
Permana, & Read, 2005). Grossberg and colleagues (2004) demonstrated that adherence,
as measured by time-to-pharmacy refill, was able to distinguish an HIV RNA impact
among individuals self-reporting perfect adherence. Patients who were adherent to
HAART as measured by consistent pharmacy refills for greater than 4 months were
significantly more likely to achieve virologic control and immunologic benefit than were
less-adherent patients (Maher et al., 1999). Using pharmacy-based adherence measures,
Kitahata et al. (2004) determined that higher levels of adherence to HAART were
significantly associated with longer time to virologic failure, greater increase in CD4
lymphotcyte count, and lower risk of progression to clinical AIDS or death. After
controlling for other factors, patients with low adherence had over five times the risk of
disease progression in patients with moderate adherence, or patients with high adherence.
Assessing refill records is non-intrusive and reduces the possibility of bias in the
research process as subjects are usually not aware that their behavior is being monitored.
However, like other measures of adherence, pharmacy refill pickup does not assure that
the patient actually took the medication as prescribed (Miller & Hays, 2000b).
Combined Methods of Adherence Measurement
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To address the limitations of any one measurement approach, some researchers
have suggested that adherence measurement methods be combined (Kerr, Walsh, LloydSmith, & Wood, 2005). The use of medication diaries with computer-assisted selfinterviewing gave insight into patients’ adherence patterns (Hugen et al., 2002). Selfreported adherence data has also been shown to enhance data obtained from electronic
monitoring methods (Bangsberg et al., 2000).
Liu and colleagues (2001) examined different adherence measures applied to the
same patient and found that different methods of measurement suggested different levels
of adherence. Adherence was underestimated by EDM and overestimated by pill count
and interview. Data obtained from EDM, pill counts, and interviews were subsequently
merged into a composite adherence score (CAS). While adherence as measured by CAS,
EDM, pill count, and interview were associated with achievement of undetectable
viremia within six months of initiating HAART therapy, the CAS demonstrated the
strongest predictive relationship. Although the summary measure combining several
measures was more strongly related to a clinical response, they suggested a more
practical measurement method is needed for clinical use.
Berg and Arnsten (2006) suggested that adherence is especially difficult to
measure because it is composed of several distinct behaviors. Component adherence
behaviors include obtaining refills, ingesting the right number of pills, ingesting pills
within an effective dosing interval, and ingesting pills in accordance with any appropriate
dietary requirements. Individual measures of adherence frequently measure just one
single aspect of adherence behavior. This phenomenon of “construct underrepresentation” occurs when a measure fails to assess important dimensions of the
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construct in question (Hubley & Zumbo, 1996). Although some adherence measures
such as EDM provide the ability to measure several aspects of adherence, the data are not
generally analyzed in this manner. EDM and other measures are vulnerable to another
validity threat caused by measuring unrelated constructs. The term “construct irrelevant
variance” is used when a measure contains excess variance attributable to unrelated
constructs (Berg & Arnsten, 2006).
No single method has been established as the gold standard for measuring
adherence. Each method has advantages as well as disadvantages. The HIV treatment
guidelines published by the HIV Medicine Association of the Infectious Diseases Society
of America suggested that once an adherence assessment method has been selected, it
should be used consistently to monitor each patients’ adherence at each visit (Aberg et
al., 2004). Chesney (2006) indicated that it is unlikely that a single optimal measurement
of adherence can be found as the reasons for measuring adherence vary based on whether
the assessment is for research or clinical purposes and require further refinement based
on the research questions being investigated or the clinical needs being addressed.
Consequently, it is unlikely that a single optimal intervention can be developed because
the reasons for nonadherence are as diverse as the populations affected by HIV disease.
In summary, there is no clear and universal method to rigorously measure
individual patients’ adherence. Rigorous adherence measurement requires
interdisciplinary collaboration between social scientists and HIV researchers. Improving
the measurement of HAART adherence would facilitate the development and evaluation
of adherence-improving interventions with standardized and empirically tested adherence
measures (Berg & Arnsten, 2006).
39

Measurement of Treatment Outcomes
The success as well as failure of HIV treatment can be evaluated using virologic,
immunologic, and clinical criteria. Virologic indicators appear earliest after initiating
HAART and are represented by a decrease (in the case of success) or increase (in the case
of failure) in HIV RNA. Immunologic treatment success or failure usually occurs next
and is measured by an increase (success) or decrease (failure) in the CD4 lymphocyte
count. Although clinical treatment failure, if it occurs, usually becomes apparent much
later, clinical success can often be assessed early after the initiation of HAART as many
patients experience an improvement in HIV-related constitutional symptoms, such as
weight loss, generalized lymphadenopathy, fever, and night sweats (Hoffman, Rockstroh,
& Kamps, 2006).
Measurement of Virologic Outcomes
Virologic success is defined as a reduction of HIV RNA to below the level of
detection. This is based on an understanding that the more rapid and greater the decrease
in HIV RNA, the longer the therapeutic effect (Kempf et al., 1998; Powderly et al.,
1999). Commercially available assays which measure HIV RNA vary based on the lower
level of detection and dynamic ranges. The most common lower-level thresholds report
HIV RNA levels as less than (<) 50 copies, < 75 copies and < 80 copies based on the
testing methodology and equipment being used. While a lower level threshold of <50
HIV RNA copies is most common, there are no data suggesting less virologic success
when HIV RNA is measured with alternative thresholds (Hoffman, Rockstroh, & Kamps,
2006). Table 3 describes the common HIV RNA testing methodologies.
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Table 3
Quantitative Plasma HIV RNA Techniques
Technique
HIV RNA PCR
(RT-PCR)

Test Name
Amplicor HIV-1 Monitor
Test version 1.5

Manufacturer
Roche

Dynamic Range
< 50 – 750,000
copies/ml

Branched chain DNA
(bDNA)

Versant HIV-1 RNA 3.0

Bayer

< 75 – 500,000
copies/ml

Nucleic acid sequence-based
amplification (NASBA)

NASBA or NucliSens
HIV-1 QT

bioMerieux

<80 – 3,500,000
copies/ml

Adapted from Bartlett & Gallant (2005)

HIV RNA is the most commonly used variable used by clinicians to assess patient
measures of adherence but it is also affected by antiretroviral drug resistance and drug
bioavailability (Wagner et al., 2001). Serial measurements of HIV RNA are routinely
used to monitor the effectiveness or failure of therapy and help to determine if the
beneficial effect of treatment is being maintained or lost. A change of > 3-fold or > 0.5
log10 copies/ml is considered significant (Bartlett & Gallant, 2005; Steinhart, Orrick, &
Simpson, 2002).
Measurement of Immunologic Outcomes
Immunologic treatment success is broadly defined as an increase in the CD4
lymphocyte count. It is difficult to individually predict the immunological success of
therapy for patients on HAART as it varies significantly from one person to another.
Although individual research studies may have precise operational definitions of
immunologic success, no standard definition exists (Hoffman, Rockstroh, & Kamps,
2006). Immunological treatment success is not always associated with maximal viral
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suppression as even partial suppression can result in a significant CD4 lymphocyte
response (Ledergerber et al., 2004).
Serial measurements of CD4 lymphocytes are routinely used to monitor the
immunologic response to therapy. In the absence of HAART, the average rate of CD4
lymphocyte decline is 4% per year for each log10 HIV RNA copies/ml. There is a great
variability in CD4 lymphocyte test results. For example, the 95% confidence range for a
true count of 200 CD4 lymphocyte cells per millimeter3 is 118-337 cells per mm3
(Bartlett & Gallant, 2005). Several factors can influence the variability of CD4
lymphocyte counts including laboratory analytical variation and seasonal and diurnal
fluctuations. CD4 lymphocyte counts are also used to stage HIV disease and guide
prophylactic treatment. A CD4 lymphocyte count <200 copies/mm3 indicates severe
immunodepression and is a diagnostic marker of AIDS (Bartlett & Gallant, 2005;
Steinhart, Orrick, & Simpson, 2002).
Measurement of Clinical Treatment Outcomes
Clinical treatment success is dependent on virologic and immunologic success
and has been reported in numerous studies (Ledergerber et al., 2004; Salzberger et al.,
1999). Clinical response is not always easy to assess as there is no way to show what
might have occurred if treatment had not been initiated. Clinical success is usually
evaluated based on either the absence of clinical endpoints such as AIDS-defining
illnesses or death or an improvement in, or resolution of, HIV-related constitutional
symptoms such as weight loss, generalized lymphadenopathy, fever, and night sweats
(Bartlett & Gallant, 2005; Hoffman, Rockstroh, & Kamps, 2006).
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Impact of Medication Adherence on Immunologic and Virologic Outcomes
Adherence to HAART has been shown to be an important predictor of virologic
suppression and of clinical outcomes (Gross, Bilker, Friedman, & Strom, 2001; McNabb
et al., 2001; Paterson et al., 2000). HAART adherence is the second strongest predictor
of progression to AIDS and death, after CD4 lymphocyte count (Bangsberg, Perry et al.,
2001; Garcia de Olalla et al., 2002; Hogg et al., 2002). In a meta-analysis of randomized
controlled trials (RCTs ) of interventions for adherence to HAART, Simoni and
colleagues (2006) found that across 19 RCTs with more than 1800 participants, those
who received an adherence intervention were 1.5 times as likely to report 95% adherence
and 1.25 times as likely to achieve undetectable HIV RNA levels as participants in
comparison conditions.
CD4 lymphocyte response can be somewhat delayed following initial HAART
initiation. For this reason, many experts believe that HIV RNA is the best measure of
therapeutic response to HAART (Nieuwkerk & Oort, 2005). Bartlett and Gallant (2005)
believe that the CD4 lymphocyte response is the best clinical prognostic indicator.
Adherence Interventions: Review of Studies
Introduction
Increasing recognition that medication adherence is a determinant of treatment
outcomes has generated a number of studies investigating methods to support and
improve adherence. While early research studies on this topic were primarily based on
small pilot and feasibility studies and had minimal empiric validity, there has been an
increase in the number of RCTs with adequate sample sizes emerging over the last few
years (Simoni, Pearson, Pantalone, Marks, & Crepaz, 2006). In general, patients who
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receive interventions for adherence are more likely to achieve higher levels of adherence
and are more often able to achieve undetectable HIV RNA levels than participants in
various controlled conditions (Chesney, 2006). Adherence interventions are costeffective, and are likely to provide long-term survival benefit to patients (Freedberg et al.,
2006).
This section will review and summarize studies related to HAART adherence
interventions. Interventions will be categorized as 1) patient education and counseling
strategies; 2) directly observed therapy; and 3) adherence devices and reminders.
Studies are often characterized as: 1) cognitive (designed to teach, clarify, or instruct); 2)
behavioral, such as those designed to shape, reinforce, or influence behavior; or 3)
affective, such as those designed to optimize social and emotional support.
Patient Education and Counseling Interventions
The majority of adherence interventions reported in the literature involve
dedicated time with patients to plan for and support medication adherence. The
frequency and nature of these interventions varied, but those that appeared effective were
characterized by an initial education session followed by ongoing sessions maintained
regularly over the course of treatment (Machtinger & Bangsberg, 2006). These studies
typically involved cognitive interventions or educational interventions targeting patient
knowledge of drug therapy and employed methods such as counseling by a nurse
educator, clinical pharmacist, or physician. Cognitive interventions typically provided
general information such as dosing instructions, medication description, drug interaction
information or general information about HAART options.
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A wide range of behavioral strategies have been implemented including the use of
pillboxes, using a register to record administered medications, role-playing medication
schedules and schedule adjustments, using behavioral problem-solving groups, teaching
self-monitoring skills, and identifying risk factors for nonadherence. Some studies used a
combination of interventions including cognitive and behavioral methods such as
describing dosing instructions and graphs of HIV RNA levels or educational sessions
with an adherence counselor and a weekly pill container. Some studies contained three
interventions including cognitive, behavioral, and affective techniques.
Several published studies have tested educational interventions involving
healthcare professionals teaching patients about their medications, the importance of
adherence, and methods to strengthen adherence. While several researchers found that
educational interventions had a sustained impact on adherence (Goujard et al., 2003),
others found minimal or no effect (Rawlings et al., 2003; Remien et al., 2005).
Virologic and immunologic impact was inconsistently observed. Adherence
measurement methods also varied among these studies with EDM and self-report being
most common. One researcher utilized cue-dosing (timing doses around meal times or
regular daily activities) and monetary reinforcement to remind patients to take their
medications and observed an improvement in adherence that was not sustained and
returned to baseline with discontinuance of the intervention (Rigsby et al., 2000).
Two studies examined the effect of pharmacist-led adherence sessions (Haddad et
al., 2000). Although patients who received the intervention self-reported higher levels of
adherence, virologic improvements were only seen in one study (Rathbun, Farmer,
Stephens, & Lockhart, 2005). Knobel (1999) administered individual advice regarding
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adherence and the effect was measured with structured interview and pill counts. Those
who received individual counseling had significantly better adherence rates than those
who did not, but there was no significant difference in virologic response.
Several studies have tested motivational interviewing and cognitive-behavioral
problem-solving approaches to improve adherence. Adherence was consistently higher
in patients who received these interventions. While Safren et al. (2001) found little
difference between patients that received a single intervention session compared with
patients who simply maintained a pill diary and completed an adherence questionnaire,
patients who received motivational interviewing led by nurses reported higher medication
adherence than those receiving usual care and were more likely to follow the medication
regimen as prescribed by their health care provider (DiIorio et al., 2003).
In another study, patients received 10 sessions of cognitive-behavioral stress
management and expressive supportive therapy (Jones et al., 2003). Participants were
assessed on self-reported medication adherence over seven days along with coping
strategies and beliefs related to HAART. Patients with low baseline adherence that
received the intervention significantly increased their mean self-reported adherence by
approximately 30%. Those in the usual care group showed a non-significant increase in
adherence. After receiving monthly cognitive behavior therapy sessions over a one year
period, Weber (2004) found that patients’ mean adherence as measured by EDM was
similar between the intervention and standard care group. While the proportion of
patients with adherence levels > 95% was significantly higher in the intervention group,
virologic outcomes in both groups were similar.
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Smith, Rublein, Marcu, Brock and Chesney (2003) examined the effect of a selfmanagement intervention based on feedback of adherence performance and principles of
social cognitive theory on adherence. Individuals in the self-management group were
significantly more likely to take 80% or more of their doses each week than individuals
in the control group as measured by EDM.
In summary, some improvement in adherence has been seen with education and
counseling-based interventions but the results were inconsistent and frequently
diminished when the intervention was terminated. Significant immunologic and
virological improvements were inconsistently observed.
Directly Observed Therapy
Directly observed therapy (DOT) has been studied as an adherence intervention
based on its successful use in treating nonadherent tuberculosis patients. Fischl (2001)
and her team compared patients receiving DOT in a correctional facility to those
receiving standard outpatient clinic services and found that patients who received DOT
had a significantly higher chance of achieving undetectable HIV RNA than those that
received standard clinic care.
Altice, Mezger and Bruce (2003) compared DOT for once- daily dosing, modified
DOT (twice-daily dosing in which one dose was give via DOT) and standard care. The
patients receiving DOT had significant improvements in three-day self-reported
adherence, six-month median CD4 lymphocyte response, and six months median
reduction of HIV RNA. In another study, pregnant women who were identified as being
at very high risk for HAART nonadherence and consequent mother-to-child transmission
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were given DOT during the third trimester of pregnancy. Clinical outcomes of no
perinatal transmission of HIV, suppression of HIV RNA, and receipt of appropriate
antiretroviral agents during labor were similar to those that received standard care
(Bryant, Collingham, & Till, 2004).
While studies of DOT have resulted in improvements in clinical outcomes
associated with HAART, DOT programs may not be appropriate for most clinical setting
as they are expensive, labor-intensive and frequently perceived by patients as intrusive
(Liechty & Bangsberg, 2003). Machtinger and Bangsberg (2007) believe that the best
candidates for DOT are those with low motivational states who have experienced failure
with less intensive adherence support and who have advanced HIV disease.
Adherence Devices and Reminders
A number of devices are available to help patients adhere to their medication
regimen including medication organizers such as pillboxes, reminder devices such as
alarm watches and pagers, and visual medication schedules. Golin and her team (2002)
found that patients who used more adherence aids were more adherent. The
manufacturers of electronic drug monitoring devices have even added clocks and alarms
to their equipment to help remind patients to take their medication as prescribed (Miller
& Hays, 2000a). Most devices are simple, inexpensive, and easy to integrate into the
routine care of patients. Pill boxes allow patients to organize their doses of medication in
a convenient location. They eliminate the need to carry multiple medication bottles and
provide a means to verify whether doses have been taken. Clinicians can monitor for
nonadherence if patients take pillboxes to clinical appointments. Some pharmacies
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provide medications prefilled into weekly or monthly organizers (Machtinger &
Bangsberg, 2006; Machtinger & Bangsberg, 2007).
While the success of these devices has primarily been reported based on clinical
and field experience, several research studies have been conducted related to this area.
McPherson-Baker et al. (2000) prospectively studied patients who participated in weekly
sessions using pillboxes combined with monthly individualized adherence counseling.
After five months, those receiving the intervention had a significant improvement in their
adherence as measured by pharmacy refill data and fewer hospitalizations.
Because many patients cite ‘forgetting’ as a primary reason for missing doses of
HAART, reminder devices such as alarms on watches, pagers and other electronic
technology are recommended to provide multiple daily reminders (Chesney, 2000;
Chesney, Morin, & Sherr, 2000). Andrade et al. (2005) measured the effect of a
memory-prompting device combined with monthly adherence counseling on adherence to
HAART in memory-intact and memory-impaired subjects in a prospective RCT. Mean
adherence scores as measured by EDM did not differ between the intervention and
control group. However, a subset of memory-impaired patients who received the
intervention had significantly higher levels of adherence.
Safren and his team (2003) tested a customizable reminder system using webbased pager technology to increase and maintain adherence in patients with pre-existing
adherence problems. After a two-week monitoring period with EDM, participants with
less than 90% adherence were randomized to continue monitoring or to receive a pager.
Compared to standard care, the group who received the pagers had greater improvements
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in adherence through the first three months but adherence at the end of the study was still
poor in both groups. Safren suggested that more intensive interventions are required for
patients with pre-existing problems.
Visual medication schedules contain pictorial displays of HAART agents
superimposed on calendars as visual reminders of which pills to take and at what times.
Although not tested in patients receiving HAART, Schillinger (2003) found that these
visual schedules improved outcomes in patients receiving anticoagulation therapy
(another chronic disease state involving daily medication that requires high levels of
adherence).
Qualitative Reviews and Meta-Analyses of HAART Interventions
The literature related to HAART adherence interventions has been reviewed
several times. Early qualitative reviews indicated that reports were based primarily on
small pilot and feasibility studies and offered few prescriptive guidelines with minimal
empiric validity. While later reviews highlighted the improved rigor of the studies,
considerable variation in sampling and assessment strategies, intervention components,
and findings was noted (Simoni, Pearson, Pantalone, Marks, & Crepaz, 2006).
Fogarty et al. (2002) published the first comprehensive literature review all of
published articles reporting interventions designed to increase adherence to HAART.
Although 16 interventions were identified employing a wide range of behavioral,
cognitive and affective strategies, only 11 included data on intervention and efficacy and
the effects of these interventions were generally weak.
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Simoni, Pantalone, Frick and Turner (2005) performed a meta-analysis of 15
randomized controlled trials related to adherence interventions and found some
significant differences in either adherence or clinical impact between the intervention and
control arms in 10 of the studies. They noted several significant concerns: 1) the findings
were difficult to interpret due to the heterogeneity in the studies; 2) the duration of
treatment intervention varied from 1 to 10 sessions with ongoing follow-up ranging
anywhere from 1 day to more than 1 year; 3) the methods used to assess adherence varied
from different types of self-report to EDM; and 4) measurement of immunologic and
virologic response was uncommon. Improvement in adherence was not commonly
sustained. Unfortunately, findings from similar interventions were inconsistent. For
example, in two studies, cognitive-behavioral treatment was part of a successful strategy
(Safren et al., 2001; Weber et al., 2004) but in two others it was not (Jones et al., 2003;
Murphy, Lu, Martin, Hoffman, & Marelich, 2002). Simoni's (2005) review of the
literature suggested a lack of empirical data necessary to make strong recommendations
regarding the most efficacious way to improve adherence to HAART.
Simoni and her team (2006) conducted another meta-analysis to determine
whether behavioral interventions addressing HAART adherence were successful in
increasing the likelihood of a patients attaining 95% adherence or undetectable HIV
RNA. Nineteen studies with a total of 1839 participants met their selection criteria of
describing a randomized controlled trial among adults that evaluated a behavioral
intervention with HAART adherence or HIV RNA as an outcome. Random-effects
models indicated that across studies, those who received an adherence intervention were
1.5 times more likely to report 95% adherence and 1.25 times more likely to achieve an
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undetectable HIV RNA compared to participants who did not receive an intervention.
The intervention effect for 95% adherence was significantly stronger in studies that used
recall periods of 2 weeks or 1 month as compared to 7 days or less. They concluded that
more research is needed to identify the most efficacious intervention components and the
best methods for using them in actual clinical settings (Simoni, Pearson, Pantalone,
Marks, & Crepaz, 2006).
Amico, Harman and Johnson (2006) performed a research synthesis of HAART
intervention outcome studies published between 1996 and 2004. Effect sizes were
calculated for each study outcome resulting in 25 immediate post-intervention outcomes
and an additional 13 follow-up effect sizes. They found small effect size (d = 0.35, odds
ratio [OR] = 1.88) that varied considerably across studies. Interventions that specifically
enrolled participants with known or anticipated problems with HAART adherence
demonstrated medium effects on adherence (d = 0.62, OR = 3.07). Interventions that did
not target their participants on similar criteria had small effects (d = 0.19, OR = 1.41).
Adherence improvements showed no tendency to decay with time. The authors
concluded that adherence intervention outcome studies must carefully delineate their
target populations because defining individuals as "on HAART" does not provide the
level of specificity needed to design and implement effective adherence interventions.
Given the relatively small effects observed from studies of single adherence
interventions and in an effort to expand the breadth of adherence issues addressed by
these interventions, combinations of adherence interventions are suggested by many
adherence experts. Studies of patients with other chronic diseases suggest that
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approaches addressing only one factor related to adherence will not be as powerful as
interventions addressing multiple factors (Miller & Hays, 2000a).
Despite the need for programs and procedures that support or enhance adherence
to HAART, little evidence exists about the extent to which clinical practices have been
able to incorporate adherence interventions into their routine care. Investigators
conducted a survey of clinical care settings in New York and Connecticut and determined
that the current standard of care is to provide only minimal levels of adherence services.
They also found that ad hoc adherence support was frequently offered on an as-needed
basis (Harman, Amico, & Johnson, 2005). These findings support the need for the
ongoing development of adherence interventions that are easily translatable to real-life
clinical practice.
In some cases an intervention can become the standard of care despite the empiric
data demonstrating its efficacy. In these cases it may be considered unethical to assign
patients to the control arm of a trial. For example, randomized controlled trials have
provided evidence that behavioral interventions improve adherence to HAART. Such
interventions are increasingly considered the standard of care, making additional
randomized trials less likely (Petersen, Wang, van der Laan, & Bangsberg, 2006).
In the absence of conclusive empirical data, clinicians have frequently turned to
adherence strategies recommended by experts which are based on limited data, research
from adherence in other disciplines, clinical practice experience and demonstrated
correlates of adherence (Simoni, Pantalone, Frick, & Turner, 2005). For example, the
Best Practices Guide, published online by the American Public Health Association (Jani,
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2002) proposes a practical four step approach in the management of adherence: 1) assess
factors that may influence adherence and function as potential barriers; 2) develop and
maintain a therapeutic alliance with the patient; 3) monitor the level of adherence using
multiple measures; and 4) implement multiple targeted interventions to resolve barriers to
adherence. Chesney (2003), Turner (2002) and the American Psychological Association
(1997) offered similar adherence management guidelines and recommendations which
are summarized in Table 4.
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Table 4
Adherence Management Guidelines and Recommendations
Turner

APA

Chesney

Simplify and explain the
treatment regimen.

Clarify the regimen.

Deliver an introductory
statement.

Provide reminder
devices.

Tailor it to individual lifestyles.

Confirm understanding of the
regimen.

Discuss potential side
effects.

Facilitate interaction with clinic
staff.

Assess adherence.

Provide social support.

Identify and remove personal
barriers to adherence.

Ask about reasons for
missing doses.

Treat concomitant
psychological disorders
and substance abuse
problems.

Refer patients with special needs
such as substance abuse to
appropriate treatment.

Ask about medication side
effects or other problems.

Enhance self efficacy: offer positive
feedback for new skills,
demonstrated problem-solving and
ways to integrate the regimen into
their lives.
Create a social environment
conducive to adherence: enlist
support from patient's social
network and maintain support of the
clinical team.
Adapted from Turner (2002)

Adapted from APA (1997)

Adapted from Chesney (2002)

Summary
Improving adherence to HAART may require a combination of methods
appropriate to the patient and clinical setting. Alterable factors known to impact
adherence, such as depression, substance abuse, and the therapeutic relationship between
patient and provider should be addressed in a proactive and ongoing manner. Adherence
interventions should include dedicated educational and collaborative time with patients to
55

plan for medication adherence and to maintain necessary support and collaboration
throughout the course of treatment. In this way, problems such as side effects can be
addressed, medications simplified or changed if necessary, and adherence devices
supplied as deemed appropriate. Most of the adherence intervention strategies studied to
date have focused on factors directly related to patient behaviors. Other variables known
to impact adherence have not been thoroughly studied including factors related to the
healthcare provider, the patient-provider relationship, factors related to the treatment
regimen or illness, environment factors and contextual factors (Simoni, Pantalone, Frick,
& Turner, 2005).
As successfully tested interventions emerge in the literature, it is critical that the
information be disseminated into clinical practice. The issue of efficacy versus
effectiveness will need to be addressed because what works successfully in a researchbased trial may not work in clinics which face challenges such as limited staff and
resources as well as diverse patient populations (Simoni, Pantalone, Frick, & Turner,
2005).
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CHAPTER THREE: METHODS
Introduction
This chapter presents the research methods and procedures for this study. It
includes treatment conditions, background information related to the structured adherence
intervention, the study design, description of the study population and setting, inclusion
and exclusion criteria, data collection procedures, data management, and the data analysis
plan.
Treatment Conditions
Overview of the Study
This retrospective comparative study compared treatment response, pharmacy
refill adherence, and self-reported medication adherence between two groups of patients:
those participating in an AIDS Drug Assistance Program (ADAP) and those participating
in a Medicaid-funded medication access program. The ADAP served as a structured
adherence intervention (SAI) based on procedural and administrative processes required
by the state-managed program. Those patients receiving antiretroviral medications as
part of the Medicaid-funded program were considered usual care as this program did not
contain systematic procedural and administrative conditions which could impact
adherence. A number of other variables can impact medication adherence including
adherence interventions (adherence counseling, education, and aids), ARV-related
factors, sociodemographic factors, and HIV disease specific factors. Figure 1 depicts the
conceptual model developed to structure this study based on existing research findings.
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Figure 1. Conceptual Model for Evaluating the Effects of a Structured Adherence
Intervention to HAART on Adherence and Treatment Response Outcomes.
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Structured Adherence Intervention
Introduction: National AIDS Drug Assistance Program
The AIDS Drug Assistance Program (ADAP) is a federal program administered
by each state to provide medications for the treatment of HIV disease. Eligibility to
participate in the ADAP is based on the lack of adequate health insurance and financial
resources necessary to cover the cost of medications. While some clients are enrolled in
ADAP on a long-term basis, others participate temporarily while they await acceptance
into other insurance programs. Each state AIDS Drug Assistance Program is unique in
which medications are included in its formulary and how those medications will be
distributed (Department of Health and Human Services, 2007).
Florida AIDS Drug Assistance Program
The ADAP for the State of Florida is centrally administered by the Bureau of
HIV/AIDS in Tallahassee. The most populated counties within the state have local
ADAP offices based in the respective county health department to serve the nearby
residents. Smaller counties with lower numbers of HIV-infected patients are served via a
central pharmacy in Tallahassee. Program policies and procedures are published in the
ADAP Program Manual and serve as the operating standards for each ADAP office
within the State (Florida Department of Health, 2007).
The goals of the Florida ADAP are to: 1) establish a program to provide
therapeutics to treat HIV disease or prevent deterioration of health arising from HIV; 2)
provide access to HIV treatments for low income, indigent persons who have no other
resource to attain needed medications; 3) facilitate access to the program; 4) provide
outreach to individuals with HIV and their families; and 5) provide program and
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procedural technical assistance and guidance to county health departments to facilitate
service to eligible persons. Two additional goals are explicitly related to adherence: 1)
to help patients adhere to their treatment regimens and 2) to assist patients in avoiding
interruption in ARV regimens (Florida Department of Health: Bureau of HIV/AIDS,
2003).
Many of the standards associated with the Florida ADAP are consistent with
current recommendations and guidelines found in the Department of Health and Human
Services (DHHS) treatment guidelines (National Institutes of Health, 2006). For
example, clinical eligibility to start antiretroviral therapy with the Florida ADAP mirrors
the recommendations of the DHHS for initiation of HAART. Similarly, the ADAP
requires ongoing HIV RNA measurement and CD4 lymphocyte counts every three to
four months to monitor response to treatment as recommended by the DHHS.
Although the ADAP is primarily a medication access program, administrative
functions incorporate actions to monitor and reinforce adherence to HAART. The
Florida ADAP Program Manual addresses a number of issues related to HAART
adherence which are summarized in Table 5.
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Table 5
Adherence-Related Statements in the Florida ADAP Program Manual
1.

Any department-specified or local health department adherence policy and/or
procedure must be followed in educating and counseling the patient about taking
medications.

2.

If there are problems with adherence, especially if a change in the HAART regimen
is due to nonadherence, the patient's case manager and healthcare provider should
be notified.

3.

Patients in the Florida ADAP may be disenrolled if the patient fails to pick up
medications for more than 60 days and or is refusing to adhere to the medication
regimen despite counseling and supports or other assistance offered. This decision
should be made with the treating healthcare provider's input and guidance.

4.

Patients are responsible for picking up their medications on time each month before
they run out.

5.

It is the goal of the ADAP to help patients adhere to their treatment regimens.

6.

Patients have to cooperate in picking up medication and providing required
information as requested or required.

Adapted from Florida Department of Health: Bureau of HIV/AIDS. (2003). AIDS Drug Assistance
Program Manual (ADAP). Tallahassee: Florida Department of Health.

The Florida ADAP Program Manual also addresses patients who are nonadherent
to HAART. Nonadherence is defined as not picking up HAART agents from the
pharmacy within 35 days of the last pharmacy refill (Florida Department of Health:
Bureau of HIV/AIDS, 2003). The statements in Table 6 summarize the process that
ADAP staff is expected to follow when a nonadherent patient is identified.

61

Table 6
Florida ADAP Procedures Related to Nonadherence and Failure to Pick-up
1.

2.

3.

4.

5.

6.

If the patient is five or more workdays late for a scheduled medication pickup:
• An inquiry should be initiated to determine the reason for the delay in picking up
medications.
• The case manager and treating healthcare provider must be notified as soon as possible.
• A determination should be made as to whether or not the patient has had an interruption in
drug therapy. If the patient last picked up a 30 day supply of medication, and has not been
back to pick up for 35 or more days, then there has been an interruption in therapy.
• If there has been no interruption in drug therapy, the patient should be encouraged and
assisted in getting his or her medications for the month.
• If there has been an interruption in drug therapy of five or more days, a consultation with the
treating healthcare provider should be made as soon as possible before the patient is allowed
to pick up his or her medications for the month.
Patients who report "borrowing" or using another patient's medications to continue their own
treatment are still considered to have an interruption in therapy if medications were issued by the
Department more than 35 days prior.
• Patients who report using "leftover" medications in their possession also may have been
nonadherent.
• Patients should not be given medications until the healthcare provider has been consulted
and has given approval to issue medications or other instructions.
If the patient fails to show at all for three weeks to 30 or more days to pick up medications, the
treating healthcare provider and case manager must be notified.
• If the patient comes in for medication at this point, he or she must see the treating healthcare
provider before being given medication.
• If the treating healthcare provider states that an office visit is not needed or desired, and
wants medication issued, give the patient medications and document the name of the
healthcare provider's staff who gave the instruction to issue the medications.
If the patient fails to show at all for 60 days or more, he or she should be closed out of the ADAP
system.
• Notify the case manager and the healthcare provider that the patient has not picked up
medication for 60 days prior to closure.
• If the patient shows up in 60 days and has not been closed, he or she must see the treating
healthcare provider, have new labs, and obtain prescriptions.
If the patient has missed 90 days or more of medication, has not already been closed out, and comes
in, no medications can be given.
• The patient must see the treating healthcare provider, provide new labs and obtain new
prescriptions.
• Notify the healthcare provider and the case manager that the patient has missed 90 days of
medication.
Documentation of contact with the patient and the healthcare provider must be placed in the patient
record.
• Patients who decide to stop drug therapy without the knowledge or consent of their treating
healthcare provider should be advised to contact him or her.
• Notice of therapy interruption should be given to the healthcare provider by the ADAP
contact.

Adapted from Florida Department of Health: Bureau of HIV/AIDS. (2003). AIDS Drug Assistance
Program Manual (ADAP). Tallahassee: Florida Department of Health.
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The Florida ADAP is unique with their approach to closely and regularly monitor
medication refill adherence as part of the program’s standard of practice. ADAP staff
records the date that patients pick up their medications from the pharmacy in each
patient’s record. The program provides a 30 day maximum supply of ARV medication.
Prescriptions can be refilled 28-35 days after the previous prescription has been
dispensed. Programmatic standards state that if the patient is five or more workdays late
for a scheduled medication pickup, an inquiry should be initiated to determine the reason
for the delay in picking up medications. The case manager and treating healthcare
provider must be notified as soon as possible. A determination should be made as to
whether or not the patient has had an interruption in drug therapy which they define as a
time lapse of 35 or more days since the patient last picked up a 30 day supply of
medication (Florida Department of Health: Bureau of HIV/AIDS, 2003).
If there has been no interruption in drug therapy, the patient is encouraged and
assisted in getting his or her next supply of monthly medications. If there has been an
interruption in drug therapy of five or more days, a consultation with the treating
healthcare provider is made as soon as possible before the patient is allowed to pick up
his or her medications for the month. The treating healthcare provider can either approve
additional medication dispensing or hold further medication dispensing. If dispensing is
put on hold, the healthcare provider usually schedules a face-to-face meeting with the
patient or requires that the patient schedule an appointment with the adherence specialist
for additional assessment and intervention. It is this medication refill monitoring process
that serves as the main monitoring component for the structured adherence intervention in
this study.
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Usual Care
Usual care in this study included patients that received their antiretroviral therapy
from Florida Medicaid. Like the ADAP, this program also provided a 30 day supply of
medication but did not contain procedural or administrative conditions which could
impact adherence. Healthcare providers were not informed of missed or late pharmacy
refills. It is theoretically possible that a patient could fail to pick-up any medication or
could pick up medication refills erratically without the prescriber’s knowledge.
Medication Adherence Assessment
Providers of the outpatient HIV treatment program monitor self-reported
medication adherence at each clinic visit for patients participating in the ADAP and usual
care programs. During the routine clinic intake process, a medical assistant asks each
patient several adherence related questions and documents responses on a clinic-designed
Medication Adherence Assessment Form. Although no validity or reliability testing has
been performed on this specific assessment tool, self-reported adherence based on patient
recall of the number of doses missed in the last 7-30 days has been reported in the
literature as a valid indicator of adherence (Haubrich et al., 1999; Mannheimer,
Friedland, Matts, Child, & Chesney, 2002; Montaner et al., 1998; Nieuwkerk & Oort,
2005). These self-report adherence questions are listed in Table 7.
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Table 7
Medication Adherence Assessment Questions (Self-Report)
1.

How many doses of your HIV medication have you missed in the last week (7 days)?

2.

How many doses of your HIV medication have you missed in the last month (30 days)?

3.

Are you having any side effects from your HIV medications that interfere with your ability
to take them on a regular basis?

Using the patient’s response to the medication adherence assessment, the provider
calculated an adherence rate for each patient. The monthly adherence rate was calculated
as: (1 – [missed doses in the last 30 days / prescribed doses in the last 30 days] ) X
100%. This percentage was documented in the patient’s medical record and was
subsequently entered into the LabTacker™ database by a data entry assistant.
Adherence Services and Interventions
The outpatient HIV treatment program employs a registered nurse in the capacity
of adherence specialist. The adherence specialist was available to all patients that
received care at the outpatient HIV treatment program including ADAP and usual care
patients. While most patients are referred to the adherence specialist from their
healthcare provider, patients can also self-refer to the specialist for assistance. ADAP
staff also refers patients to the adherence specialist when they identify a perceived need
for adherence assessment or intervention. Typical services and interventions provided by
the adherence specialist are summarized in Table 8.
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Table 8
Services and Interventions Provided by the Adherence Specialist
• General education related to the HIV disease process, HIV treatment medications and goals of
treatment
• General and specific information related to ARV medications including dosing, timing,
potential side effects and side effect management
• Medication scheduling assistance
• Education related to the importance of adherence, methods to prevent the development of ARV
resistance, and pharmacy and medication refill processes
• Assessment of support systems
• Identification of potential barriers to adherence
• Support and counseling
• Prescription of adherence aids: pill boxes, timers, alarm watches

Adherence interventions may include the recommendation to use a pill box, the
use of a programmable wristwatch which can display multiple digital messages to serve
as reminders throughout the day, reminder telephone calls, education, counseling, and
support. All services and materials are provided free of charge to the patient as they are
provided by Ryan White Grant funding and donations.
Documentation of adherence assessment and intervention is documented in the
clinic medical record along with the length of the visit in increments of 15 minute
sessions. The adherence specialist maintains a Microsoft® Access database containing
the patient’s self-reported adherence percentage, number of visits for adherence
counseling, length of time associated with each consultation, and interventions or aids
that were provided or recommended to the patient.
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Summary
The Florida ADAP includes a unique structured adherence intervention as a
standard component within their medication access program. Pharmacy refill data is
closely monitored by ADAP staff with the intent that patients will refill their medication
on time, month after month. After picking up a month’s supply of HAART medications,
patients have approximately a one-week period to refill their next month’s supply
beginning at day 28 and ending at day 35. ADAP staff is in close contact with pharmacy,
medical, and nursing staff to keep everyone proactively informed of patients that may
have adherence deficits. Patients who do not pick up monthly refills within the
appropriate timeframe are required to consult with the healthcare provider who may grant
permission to resume medication or may require the patient to consult with the adherence
specialist for further assessment and possible intervention. This structured adherence
process served as the primary intervention in this research study.
Research Design
Study Design
This study used a retrospective comparative design to analyze secondary data.
The study was designed to better understand the effects of a structured adherence
intervention associated with an existing medication access program on adherence to
HAART and response to HAART treatment compared to usual care. In the SAI group,
providers closely monitored monthly HAART medication refills and provided structured
adherence intervention when indicated. Patients in the usual care group were enrolled in
a Medicaid-funded medication access program and did not receive ongoing medication
refill monitoring and structured adherence intervention.
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Study Population
The study population included all eligible patients participating in the Florida
ADAP or in a Medicaid-funded medication access program who received HAART
medications and outpatient HIV medical care from one single treatment center and
pharmacy in west central Florida during the calendar year 2005. This time period was
selected to minimize the influence of the implementation of Medicare Part D prescription
medication coverage which was initiated in January 2006. The implementation of
Medicare Part D prescription drug coverage had the potential to introduce additional
confounders as the process was complicated for patients and staff, and resulted in
difficulty in accessing medication for many individuals.
Inclusion Criteria
Included were all patients 18 years of age or older who completed a minimum of
six consecutive months in the SAI or usual care program as the sole means of obtaining
HAART medications during calendar year 2005 while on a consistent HAART regimen.
All patients received their medication from the single pharmacy associated with the HIV
treatment center.
Exclusion Criteria
Exclusion criteria included less than six months of consecutive participation in the
SAI program or usual care program, alterations to the ARV regimen during the six-month
period, or use of a pharmacy other than the on-site pharmacy.

68

Sample Size
This study used secondary data and the sample size was fixed. A preliminary
query of the database suggested there were 1,355 potential subjects eligible for
evaluation. Of these, 37% composed the usual care group while 63% composed the SAI
group.
Since the exact number of patients meeting the inclusion criteria was not initially
known, a conservative estimate of 50% (n=678) was considered for the purpose of
establishing a power analysis. Results of the analysis using this conservative estimate
should ensure that there is adequate power to conduct the proposed analyses. Results of
the power analysis for more liberal estimates of 60% and 70% of the entire population are
also provided to demonstrate the increased power available for the study should these
situations be found in the data.
Power Analysis
Power estimates were derived for multivariable logistic regression, the least
powerful and most complex of the analyses proposed in this study, thereby ensuring
adequate sample size for all of the analyses in the study. Table 9 summarizes the
estimated range of possible subjects and the respective power analysis associated with the
estimate. Power analyses were also conducted using inclusion estimates of both 60% and
70%. The power estimates are displayed in Table 9.
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Table 9
Power Estimates Based on Projected Sample Population
Database
Population (N)

Percentage of Database
Meeting Inclusion Criteria

Sample Size
(N)

Power

1,355

50%

678

0.80

1,355

60%

813

0.86

1,355

70%

949

0.91

Because of the unique nature of this study, no data were found in the literature to
suggest an appropriate effect size for this study. Therefore, effect size was chosen based
on programmatically relevant changes. For this analysis a 10% improvement response to
treatment by patients in the SAI program compared to those in the usual care program
was identified as being programmatically relevant. Based on this assumption, a
minimum sample size of 678 patients achieves a power of .80 at the .05 level of
significance when expecting a .10 effect. The power analysis was conducted using the
Power Analysis and Sample Size (PASS) statistical program (Hintz, 2001).
Setting
All patients considered for this study were enrolled in a comprehensive outpatient
HIV care program in west central Florida. This center was established in 1989 and is the
largest single public provider of HIV care on the west coast of Florida. The center serves
approximately 1500 active patients. The clinic provides multiple services including
medical and nursing care for patients with HIV disease along with pharmacy, dental, and
social services.
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Most patients were seen by their HIV care provider every one to three months.
Most patients obtained their medications at the on-site pharmacy. All medications
dispensed from the pharmacy were limited to a 30-day supply requiring prescriptions to
be refilled on a monthly basis.
Study Variables
Dependent Variables
There are two outcome variables in this study: adherence (self-reported
medication adherence and pharmacy refill adherence) and treatment response (CD4
lymphocyte response and HIV RNA response). Although adherence could be considered
a proximal outcome variable that influences treatment response, it was considered as a
terminal outcome in this study.
Self-reported medication adherence. Satisfactory adherence is defined as 90% or
more of the pills prescribed in any regimen taken in accordance with the prescription
plan. This is in agreement with the procedure from several other HIV medication
adherence studies (Gordillo, del Amo, Soriano, & Gonzalez-Lahoz, 1999; Gross, Bilker,
Friedman, & Strom, 2001). All self-reported adherence levels collected during the study
period were assessed.
Pharmacy refill adherence. Pharmacy prescription refill data is used as a
surrogate for medication-taking behavior and typically compares actual versus expected
refills. Although this method does not guarantee that the medications were ingested, it
does represent maximum probable adherence. Refill adherence is calculated as the
percentage of times the index ARV agent (protease inhibitor or non-nucleoside reverse
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transcriptase inhibitor) was refilled by the pharmacy within the 28-35 day timeframe
during the study period.
CD4 lymphocyte response. CD4 lymphocytes were measured by four commercial
laboratories using flow cytometry and hematology analyzers using fresh blood
specimens. Test results indicated the number of CD4 cells per cubic millimeter of blood
(Bartlett & Gallant, 2005). Immunologic response to HAART treatment was measured as
the change in CD4 lymphocyte count from baseline to 6 months. A stable or increasing
CD4 lymphocyte count is representative of successful HAART treatment.
HIV RNA response. Quantitative HIV RNA levels were measured by four
commercial laboratories. Test results indicated the number of copies of HIV RNA per 1
mL of plasma (Bartlett & Gallant, 2005). Virologic response to HAART treatment was
measured as the change in HIV RNA level from baseline to 6 months. An undetectable or
decreasing HIV RNA level is representative of successful HAART treatment.
Independent Variables: Treatment Conditions
Group membership (SAI versus usual care) is the independent variable of interest
in this study. The usual care group for this study included patients using Medicaid to
fund their HAART at the same on-site clinic pharmacy. The Medicaid program did not
include a specific adherence or prescription refill monitoring component. A maximum
30-day supply of medication was dispensed by the pharmacy at any one time. The SAI
includes a number of standard procedures to monitor and strengthen adherence as
described earlier.
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Independent Variables: Covariates
Covariates include adherence services and intervention, ARV specific factors,
self-reported medication adherence, pharmacy refill adherence, socio-demographic
factors, and HIV disease specific factors.
Adherence services and intervention. The number of face-to-face visits with the
adherence specialist during the study period, total length of time (in minutes) associated
with these face-to-face visits, and prescription of adherence aids were assessed to
compare the utilization of the adherence specialist’s services between the groups.
ARV specific factors. Characteristics related to the HAART regimen were
assessed including dosing frequency (once vs. twice daily), type of regimen based on
index agent (non-nucleoside reverse transcriptase-based vs. protease inhibitor-based), and
pill burden defined as the number of HAART pills prescribed per day.
Sociodemographic factors. Sociodemographic variables included age, gender,
race, ethnicity, income level, housing status, and health insurance.
HIV disease specific factors. These clinical covariates included risk factor for
HIV transmission, the number of years diagnosed with HIV infection, stage of disease
(HIV vs. AIDS), and the presence of comorbid conditions known to impact HAART
adherence including the presence of active substance abuse and active mental health
disorders (depression, bipolar disorder and anxiety disorder).
Tables 10 and 11 list all variables considered in this study with detailed
information related to the source of the data, frequency of measurement, operational
definition and level of measurement.

73

Table 10
Variables, Definitions and Measurement (Part I)
Source of
Data
Dependent Variables
Medication
LabTracker™
Adherence:
Self Report

Frequency

Operational Definition /
Measurement

Month 0, 3
and 6

Self-reported number of ARV
medication doses missed in the last
7 days. Adherence calculated as: (1
– [missed doses / prescribed doses])
X 100%. Average adherence >/=
90% = 1; <90% = 0.
Percentage of times the index ARV
medication (PI or NNRTI) was
refilled by the pharmacy within the
28-33 day timeframe during the sixmonth study period. Average
adherence >/= 90% = 1; <90% = 0.
Change in value from month 0-6.
No change or increase = 1;
Decrease = 0.

Nominal

Change in value from month 0-6.
No change or decrease = 1;
Increase = 0.

Nominal

Structured Adherence Intervention
or Usual Care

Nominal

Male, Female, Transgender
Age in years

Nominal
Continuous

White, Black, Asian/Pacific
Islander, Native American
(Alaskan), Multiple
Hispanic,
< 100% FPL, 101-200% FPL,
201-300% FPL, >300% FPL
Permanent, Nonpermanent
None, Medicaid, Medicare,
Medicaid and Medicare,
Hillsborough HealthCare

Nominal

Medication
Adherence:
Pharmacy
Refill

Pharmacy
administrative
database

Month 1,
2, 3, 4, 5,
6

Immunologic
Response:
CD4
Lymphocyte
Virologic
Response: HIV
RNA

LabTracker™

Month 0, 6

LabTracker™

Month 0, 6

Independent Variables
Treatment Condition: Group Membership
Covariates
Sociodemographic Factors
Gender
LabTracker™
Age
LabTracker™
Race

LabTracker™

Baseline
Start of
study
period
Baseline

Ethnicity
Income level

LabTracker™
LabTracker™

Baseline
Baseline

Housing Status
Health
Insurance

LabTracker™
LabTracker™

Baseline
Each
encounter
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Level of
Measurement

Nominal

Nominal

Nominal
Ordinal
Nominal
Nominal

Table 11
Variables, Definitions and Measurement (Part II)
Source of
Data

Frequency

HIV Disease-Specific Factors
HIV Risk
LabTracker™
Factor

Baseline

Disease Stage

LabTracker™

Baseline

HIV Disease
Status

LabTracker™

Active
substance
abuse
Presence of
MH disorder

LabTracker™

Once
(study
entry)
Month
1,2,3,4,5,6

LabTracker™

ARV Specific Factors
Dosing
LabTracker™
frequency
Type of
LabTracker™
regimen
Daily pill
LabTracker™
burden

Operational Definition /
Measurement

Level of
Measurement

MSM, Heterosexual, IDU, MSM
and IDU, Tissue/Blood Transfusion,
Hemophilia, Perinatal, Unknown
Number of years the subject has
been living with HIV Disease
calculated as length of time from
the first HIV-positive antibody test
to the date of study entry
HIV or AIDS

Nominal

Yes, No

Nominal

Month
1,2,3,4,5,6

Yes, No

Nominal

Baseline

One daily, twice daily

Nominal

Baseline

PI based, NNRTI based

Nominal

Baseline

Number of total ARV pills taken
per day

Continuous

Number of face-to-face visits with
Adherence Specialist during study
period.

Continuous

Total time in minutes of face-toface visits with Adherence
Specialist

Continuous

Yes/No

Nominal

Adherence Services and Intervention
Number of
Adherence
Month
Face-to-face
database
1,2,3,4,5,6
adherence
counseling
visits
Time
Adherence
Month
associated with database
1,2,3,4,5,6
face-to-face
adherence
counseling
Adherence aids Adherence
Month
prescribed
database
1,2,3,4,5,6
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Nominal
Interval

Data Sources
Data were obtained from several electronic databases. This section will review
the data sources, validity of data, methods associated with the process of obtaining deidentified data, data management, and security.
LabTracker™ (Ground Zero Software, 2007) software has been used as the
primary database for clinical and administrative data for over four years.
Sociodemographic data are reassessed at the patient’s first outpatient visit in each
calendar year by an advanced registered nurse practitioner or a physician. These data are
subsequently entered and updated in the LabTracker™ system by two dedicated data
entry assistants. Validity of data is continually monitored by a registered nurse and an
advanced registered nurse practitioner who compare Lab Tracker™ data to medical
record data and laboratory report forms to assure congruence. Accuracy of data is
externally audited twice a year by two independent agencies to assure accuracy of
recorded data and has consistently been 97-100% accurate when compared to medical
record data and laboratory reports.
Pharmacy data was stored in the Pharmacy Management System (PMS) (Etreby
Computer Company, 2007). Data was entered by clinical pharmacists and pharmacy
technicians and was verified by the supervising pharmacist on an ongoing basis. Data is
externally audited for accurateness annually and has consistently been 95-100% accurate.
A Microsoft® Access database contained the adherence specialists’ utilization
data associated with each patient. Data was entered by a registered nurse working in the
capacity as an adherence specialist. Accuracy of the data is externally audited once a
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year by an independent agency to assess accuracy of recorded data and has consistently
been 98-100% accurate when compared to medical record data.
Data Collection Procedures
The health center administrator (HCA) at the clinical facility had complete access
to the LabTracker™, Pharmacy Management System, and adherence specialist data
bases. Information from all three data bases was initially linked by a four digit unique
internal identification number that is used throughout the clinical facility. Once the HCA
matched all data into one Microsoft® Excel file, the unique internal client identifier was
replaced with a randomly generated study code using Microsoft Excel’s random number
generating program.

Once the files were matched, the randomly assigned study code

number was assigned as the only means of identification, and the matching algorithm was
destroyed by the HCA.
The HCA provided the investigator with a Microsoft® Excel file containing all
data elements and variables identified in this study. The resulting data file had no direct
or indirect links that could identify any individual participant or group of participants.
Procedures
Institutional Review Boards
Approvals for Institutional Review Board (IRB) exemption were obtained from
the University of South Florida’s Office of Research, Division of Research Compliance
IRB (Appendix A) and the Florida Department of Health IRB (Appendix B). Exemption
from the IRB was granted because the study used existing data, documents, and records
that were recorded without identifiers.
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Letter of Support
A letter indicating support for the study was obtained from the director of the
clinical facility.
Data Management
The Statistical Package for the Social Sciences (SPSS) version 15.0 was used for
data analysis and data management. The data files were housed on a dual-passwordprotected network server at the clinical site with access only by the researcher and
research assistant.
Missing Data
Incomplete or missing sociodemographic information, HIV disease specific
factors, and ARV specific factors are highly unlikely as these elements are mandatory in
the LabTracker database. While missing laboratory data is also unlikely, missing CD4
lymphocyte counts and HIV RNA levels will be imputed using the mean value of a
subject’s laboratory data collected in the study period.
Data Analysis Plan
The effects of the SAI will be assessed by testing two hypotheses. The following
section describes the data analyses methods.
Hypothesis 1: Patients participating in the SAI will have higher levels of selfreported and pharmacy refill adherence compared to patients receiving usual care.
Hypothesis 2: Patients participating in the SAI program will have better
immunologic (CD4 lymphocyte) and virologic (HIV RNA) responses to HAART
compared to those receiving usual care.
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Frequency distributions and descriptive statistics on all variables were performed
to describe the study sample. There were two outcome variables in the study: adherence
and treatment response.
A series of bivariate analyses were conducted to investigate the relationship
between self-reported adherence and pharmacy refill adherence, group membership (SAI
vs. usual care) and the covariates in the study. Variables found to be independently
associated with adherence were considered for inclusion in a regression model. Logistic
regression was performed on the outcome variables to test the effects of the treatment
condition while controlling for adherence services and intervention, HIV disease specific
factors, ARV specific factors and sociodemographic factors.
A series of bivariate analyses were conducted to investigate the relationship
between CD4 lymphocyte response and HIV RNA response, treatment conditions (SAI
vs. usual care) and the covariates in the study. Logistic regression was performed on
CD4 lymphocyte response and HIV RNA response to test the effects of the treatment
condition while controlling for HIV disease specific factors, ARV specific factors and
sociodemographic factors.
Results of the study were reported as group data and no identifying information
related to any person is presented.
Summary
Chapter 3 described the operating standards within the Florida ADAP that serve
as a structured adherence intervention for patients receiving HAART and the Medicaid
program that serves as the usual care group. The adherence assessment and intervention
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processes, study design, population, setting, variables and data collection procedures
were described. Finally, the data analysis plan was summarized.

80

CHAPTER 4: FINDINGS
This chapter presents the results of this study. Following a description of the
sample and comparison of the study groups, the results of the bivariate and logistic
regression analyses are reported.
Study Sample
The initial query of the LabTracker™ database suggested 1,355 potential subjects
eligible for analysis. After inclusion and exclusion criteria were applied, 424 subjects
were eligible for analyses. The SAI group included 204 subjects (48%) while 220
subjects (52%) in the usual care group were eligible for inclusion.
Subjects Excluded from Analysis
A total of 931 subjects did not meet inclusion criteria for this study. This number
was higher than expected. The reasons for excluding these subjects are shown in Table
12. The primary reason for exclusion was not using the on-site pharmacy for ARV
medication access. Patients with Medicaid or commercial insurance could select any
community pharmacy to obtain medication. Although the usual care group in this study
also had the potential to use any community pharmacy, subjects elected to use the on-site
pharmacy at the study site.
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Table 12
Subjects Excluded from Study
Reason for Exclusion

Number Excluded (%)

Not receiving antiretroviral therapy from the on-site
pharmacy

565 (60.7)

Not prescribed antiretroviral therapy for at least 6
consecutive months

291 (31.2)

Missing data

49 (5.3)

Death during the first seven months of year 2005

26 (2.8)

Note: N = 931

In theory, these two populations should be similar with regard to sociodemographic, HIV disease characteristics and comorbid conditions. Sociodemographic
variables were available for 547 of 565 patients who did not use the on-site pharmacy.
These variables were examined using Pearson Chi-Square analysis to identify differences
between the usual care group of subjects and the subjects excluded from the study
because they did not use the on-site pharmacy. No significant differences were found
between or among the two groups. This information is displayed in Table 13.
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Table 13
Comparison of Sociodemographic Characteristics of SAI Group, Usual Care Group and
Subjects Not Meeting Inclusion Criteria
SAI

Usual
Care

Excluded from
Study

Total

n=204
Frequency (%)

n=220
Frequency (%)

n=547
Frequency (%)

N971
Frequency (%)

Gender
Male
Female

152 (74.5)
52 (25.5)

147 (66.8)
73 (33.2)

366 (66.9)
181 (33.1)

665 (68.5)
306 (31.5)

Race
White
Black
Other

123 (60.3)
76 (37.3)
5 (2.5)

106 (48.2)
110 (50.0)
4 (1.8)

264 (48.3)
272 (49.7)
11 (2.0)

493 (50.8)
458 (47.2)
20 (2.1)

Ethnicity
Non-Hispanic
Hispanic

144 (70.6)
60 (29.4)

165 (75.0)
55 (25.0)

414 (75.7)
133 (24.3)

723 (74.5)
248 (25.5)

24
107
245
128
43

55
201
423
226
66

Age at time of study (years)
18-29
30-39
40-49
50-59
> 60
Health Insurance
Yes
No

22
52
79
46
5

(10.8)
(25.5)
(38.7)
(22.5)
(2.5)

9
42
99
52
18

(4.1)
(19.1)
(45.0)
(23.6)
(8.2)

(4.4)
(19.6)
(44.8)
(23.4)
(7.9)

(5.7)
(20.7)
(43.6)
(23.3)
(6.8)

69 (33.8)
135 (66.2)

219 (99.5)
1 (0.5)

539 (98.5)
9 (1.6)

827 (85.2)
145 (14.9)

Income Level (%FPL)
<100%
124 (60.8)
101-200%
55 (27.0)
>200%
25 (12.3)

168 (76.4)
46 (20.9)
6 (2.7)

419 (76.6)
111 (20.3)
17 (3.1)

711 (73.2)
212 (21.8)
48 (4.9)

Housing Status
Permanent
Nonpermanent

215 (97.7)
5 (2.3)

534 (97.6)
13 (2.4)

950 (97.8)
21 (2.2)

201 (98.5)
3 (1.5)

HIV disease specific characteristics and comorbid conditions were also compared
between the subjects in the usual care group and the subjects excluded from the study.
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These variables were examined using Pearson Chi-Square analysis to identify differences
between the usual care group of subjects and the subjects excluded from the study
because they did not use the on-site pharmacy. No significant differences were found
between the two groups. Table 14 displays this information.

Table 14
HIV Disease and Comorbid Conditions - Characteristics of SAI Group, Usual Care
Group and Subjects Not Meeting Inclusion Criteria
SAI
n=204

Usual Care
n=220

Excluded
n=547

Total
n=971

Frequency (%)

Frequency (%)

Frequency (%)

Frequency (%)

HIV Disease Status
HIV (nonAIDS)
87 (42.6)
AIDS
117 (57.4)

68 (30.9)
152 (69.1)

172 (31.4)
375 (68.6)

327 (33.7)
644 (66.3)

HIV Risk Factor
MSM
85 (41.7)
Heterosexual 106 (52.0)
IDU
10 (4.9)
Other
3 (1.5)

61
127
26
6

152
319
63
13

298
552
99
22

(27.7)
(57.7)
(11.8)
(2.7)

(27.8)
(58.3)
(11.5)
(2.4)

(30.7)
(56.8)
(10.2)
(2.3)

Presence of Active Substance Abuse
Yes
18 (8.8)
25 (11.4)
No
186 (91.2)
195 (88.6)

67 (12.2)
480 (87.8)

110 (11.3)
861 (88.7)

Presence of Active MH Disorder
Yes
54 (26.5)
No
150 (73.5)

162 (29.6)
385 (70.4)

281 (28.9)
690 (71.1)

65 (29.5)
155 (70.5)

In summary, the sociodemographic, HIV disease, and comorbid characteristics
between the usual care group and the group excluded from the study were approximately
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equivalent. Chi-square tests were performed to look for significant differences in
characteristics between these groups. No significant differences were found.
Characteristics of the Study Sample
The mean age of the sample was 44.3 years with a range of 19-76 years (SD: 9.36
years). The majority of subjects in the sample were men (n=299; 70.5%) and selfidentified as non-Hispanic (n=309, 72.9%). The majority of the subjects were white
(n=229, 54%) and 186 (43.9%) were black. The primary risk factors associated with HIV
infection for the sample were (a) heterosexual (n=233, 55%); (b) men having sex with
men (n=146, 34.4%); and (c) injection drug use (n=36, 8.5%). The mean time living with
HIV disease was 7.6 years with a range of 1-25 years. The most common ARV regimen
in the sample was protease inhibitor based (n=235; 55.4%). Subjects had a daily pill
burden range from 2 to 15 pills per day with a mean daily pill burden of 5.
The SAI group included higher percentages of both younger patients (19-29
years) and patients in the 50-59 year age range. These differences were significant (Chisquare 15.897, df 4, p=.003). A higher percentage of white patients were seen in the SAI
group while the usual care group included a higher percentage of black subjects. These
differences were significant (Chi square 6.994; df 2, p=.03). Table 15 displays the
frequency and percent for the demographic factors (gender, race, ethnicity, and age) of
the patients who met inclusion criteria.
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Table 15
Sociodemographic Composition of the Study Groups
Characteristics

SAI
n = 204
Frequency (percent)

Usual Care
n = 220
Frequency (percent)

Total
N = 424
Frequency (percent)

Gender
Male
Female

152 (74.5)
52 (25.5)

147 (66.8)
73 (33.2)

299 (70.5)
125 (29.5)

Race *
White
Black
Other

123 (60.3)
76 (37.3)
5 (2.5)

106 (48.2)
110 (50.0)
4 (1.8)

229 (54.0)
186 (43.9)
9 (2.1)

Ethnicity
Non-Hispanic
Hispanic

144 (70.6)
60 (29.4)

165 (75)
55 (25)

309 (72.9)
115 (27.1)

Age at time of study (years)**
19-29
30-39
40-49
50-59
> 60

22
52
79
46
5

9
42
99
52
18

(10.8)
(25.5)
(38.7)
(22.5)
(2.5)

(4.1)
(19.1)
(45.0)
(3.6)
(8.2)

31
94
179
98
23

(7.3)
(22.2)
(42.0)
(23.1)
(5.4)

Note.*=p<.05; **=p<.01

Preliminary analyses demonstrated that several covariates had small cell sizes.
Consequently several covariates were collapsed into fewer categories to provide the
reader with more useful information related to the population. Age of the participants
was collapsed from a continuous variable to an ordinal variable with 5 age groups.
Income levels were reduced from four groups to three due to small sample size in the
upper income range. Three male transgender patients were grouped as male. Several
HIV risk factors were grouped as “other” due to small cell sizes. Finally, the number of
years living with HIV disease was collapsed into four groups.
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Health and Income Related Characteristics
Table 16 displays the frequency for housing factors, health insurance, income, and
HIV disease specific information. As expected, a higher percentage of subjects in the
usual care group had health insurance while subjects in the SAI relied on the ADAP to
fund their medication. These differences were significant (Chi-Square 109.849, df 1,
p<.0005). More subjects in the usual care group had lower income (<100 FPL) while a
higher percentage of subjects in the SAI had higher income (>200% FPL). These
differences were also significant (Chi-Square 18.5, df 2, p<.0005). There was a higher
percentage of subjects with a risk factor of MSM in the SAI and a higher percentage of
IDUs in the usual care group (Chi-square 13.364, df 3, p=.004). Lastly, there was a
higher percentage of patients with an AIDS diagnosis in the usual care group (Chi-Square
6.288, df 1, p=.012).
Substance Abuse and Mental Health Disorders
Table 17 displays the frequency and percentage of patients diagnosed as having
an active substance abuse problem or a mental health disorder (depression, bipolar
disorder, or anxiety). The SAI group and usual care group were approximately
equivalent. A total of 43 patients (10.1%) were identified as having an active substance
abuse problem while 119 (28.1%) were diagnosed as having mental health disorder.
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Table 16
Health and Income Related Characteristics of the Study Group

Characteristics

SAI
n = 204
Frequency (percent)

Usual Care
n = 220
Frequency (percent)

Total
N = 424
Frequency (percent)

Housing Status
Permanent
Nonpermanent

201 (98.5)
3 (1.5)

HIV Risk Factor**
MSM
Heterosexual
IDU
Other

85
106
10
3

(41.6)
(52.0)
(4.9)
(1.5)

61
127
26
6

(27.8)
(57.7)
(11.8)
(2.7)

146
233
36
9

(34.4)
(55.0)
(8.5)
(2.1)

88
55
36
25

(43.1)
(27.0)
(17.6)
(12.3)

89
73
41
17

(40.5)
(33.2)
(18.6)
(7.7)

177
128
77
42

(42.7)
(30.2)
(18.2)
(9.9)

Years Living with HIV
<5
6-10
11-15
>15

215 (97.7)
5 (2.3)

416 (98.1)
8 (1.9)

Income Level ***
(% Federal Poverty Level)

<100 %
101-200 %
> 200 %

124 (60.8)
55 (27.0)
25 (12.2)

168 (76.3)
46 (21.0)
6 (2.7)

292 (68.9)
101 (23.8)
31 (7.3)

Health Insurance***
Yes
No

69 (33.8)
135 (66.2)

219 (99.5)
1 (0.5)

288 (67.9)
136 (32.1)

HIV Disease Status*
HIV (non-AIDS)
AIDS

87 (42.6)
117 (57.4)

68 (30.9)
152 (69.1)

155 (36.6)
269 (63.4)

Note.*=p<.05; **=p<.01; ***p<.001
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Table 17
Substance Abuse and Mental Health Disorders in Study Group

Characteristics

History of Active
Substance Abuse
Yes
No
Presence of Mental
Health Disorder
Yes
No

SAI
n = 204
Frequency (percent)

Usual Care
n = 220
Frequency (percent)

Total
N = 424
Frequency (percent)

18 (8.8)
186 (91.2)

25 (11.4)
195 (88.6)

43 (10.1)
381 (89.9)

54 (26.5)
150 (73.5)

65 (29.5)
155 (70.5)

119 (28.1)
305 (71.9)

ARV Therapy Characteristics
Table 18 describes the use of antiretroviral therapy associated with the study
population. There was a significant difference between the groups related to the type of
ARV regimen subjects received (Chi-Square: 7.672, df 2, p=.022). More than half of the
patients in each group received a protease inhibitor-based regimen. Approximately 6%
of all patients received a non-nucleoside reverse transcriptase inhibitor (NNRTI) based
regimen during the study period with a higher percentage in the SAI group. Based on the
DHHS guidelines in place during 2005, triple-NRTI regimens were not recommended
regimens (National Institutes of Health, 2006).
The mean daily pill burden was 5.4 pills per day with a range of 2-15 pills per
day. Over two-thirds of all patients received a regimen that required twice-daily dosing.
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Table 18
Use of Antiretroviral Medications in Study Groups
Characteristics

SAI
n = 204
Frequency (percent)

Usual Care
n = 220
Frequency (percent)

Total
N = 424
Frequency (percent)

Type of Regimen*
Protease Inhibitor
NNRTI
Triple NRTI

112 (54.9)
74 (36.3)
18 (8.8)

123 (55.9)
91 (41.4)
6 (2.7)

235 (55.4)
165 (38.9)
24 (5.7)

Dosing Frequency
Once Daily
Twice Daily

59 (28.9)
145 (71.1)

`
73 (33.2)
147 (66.8)

132 (31.1)
292 (68.9)

89 (43.6)
99 (48.5)
16 (7.8)

84 (38.2)
105 (47.7)
31 (14.1)

173 (40.8)
204 (48.1)
47 (11.1)

Daily ARV Pill Burden
2-4
5-8
9-15
Note.*=p<.05

Adherence Services and Intervention
The majority of the study population (92.7%) did not receive adherence
counseling or intervention (n=393). A total of 31 patients (7.3%) received at least one
face-to-face counseling session with the adherence specialist. Subjects received
anywhere from one session to 23 sessions with a range of total counseling time from 30
minutes to 1,230 minutes. One outlier received 23 sessions with a cumulative counseling
time of 1,230 minutes. With this outlier removed from analysis, the range of counseling
time was 30-360 minutes with a mean of 91 minutes. Fewer than 4% of all patients
received adherence aids such as pill boxes, customized medication schedules, and alarm
watches (n=16). There were no significant differences related to adherence services and
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interventions between the SAI and usual care group. Table 19 displays the frequency and
percentages of adherence counseling services and interventions received by subjects.

Table 19
Adherence Services and Intervention
SAI
n = 204
Frequency (percent)

Usual Care
n = 220
Frequency (percent)

Total
N = 424
Frequency (percent)

Received Adherence
Counseling Session
Yes
No

16 (7.8)
188 (92.2)

15 (6.8)
205 (93.2)

31 7.3
393 92.7

Adherence Counseling:
(Minutes)
0
30-60
61-120
>120

188
5
9
2

Adherence Measures

(93.2)
(1.4)
(3.2)
(2.3)

393
8
16
7

(92.7)
(1.9)
(3.8)
(1.7)

188 (92.2)
12 (5.9)
3 (1.5)
1 (0.5)
0
0
0
0

205 (93.2)
11 ( 5.0)
1 (0.5)
1 (0.5)
1 (0.5)
1 (0.5)

393
23
4
2
1
1

(92.7)
(5.4)
(0.9)
(0.5)
(0.2)
(0.2)

6 ( 2.9)
198 (97.1)

10 (4.5)
210 (95.5)

16 (3.8)
408 (96.2)

205
3
7
5

(92.2)
(2.5)
(4.4)
(1.0)

Number of Face-to-Face
Adherence Counseling
Sessions (per patient)
0
1
2
3
5
>5
Adherence Aids Prescribed
Yes
No
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Self-Reported and Pharmacy Refill Adherence
Characteristics related to self-reported adherence and pharmacy refill adherence
are summarized in Table 20. Three hundred sixty-four patients (85.8%) self-reported
medication adherence of at least 90% while 60 patients (14.2%) reported adherence rates
less than 90%. A higher percentage of subjects self-reported adherence rates > 90% in
the SAI group. There were significant differences between the two groups (Chisquare:19.581, df 1, p<.0005).
Overall, adherence levels of at least 90% as measured by pharmacy refill pick-up
were lower than the self-report measurements. A greater percentage of patients in the
SAI group had pharmacy refill adherence rates > 90%. These differences were
significant (Chi-Square: 7.578, df 1, p=.006).

Table 20
Self-Reported Adherence and Pharmacy Refill Adherence
SAI
Frequency (percent)
n = 204

Usual Care
Frequency (percent)
n = 220

Total
Frequency (percent)
N = 424

Self-Report Adherence***
> 90%
< 90%

191 (93.6)
13 (6.4)

173 (78.6)
47 (21.4)

364 (85.8)
60 (14.2)

Pharmacy Refill
Adherence**
> 90%
< 90%

120 (58.8)
84 (41.2)

100 (45.5)
120 (54.5)

220 (51.9)
204 (48.1)

Adherence Measures

Note. **=p< .01; ***p<.001
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Treatment Response
The majority of subjects demonstrated a favorable (stable or increasing) CD4
lymphocyte response (63.9%). A higher percentage of these subjects were seen in the
SAI group but this was not a statistically significant finding. However, a significantly
higher percentage of patients in the SAI (79.4%) demonstrated a favorable virologic
response (stable or declining HIV RNA level) compared with 45.9% in the usual care
group (Chi-square 50.442, df 1, p<.0005). Table 21 depicts this information.

Table 21
Treatment Response by Group Membership
SAI
Frequency (percent)
n = 204

Usual Care
Frequency (percent)
n = 220

Total
Frequency (percent)
N = 424

CD4 Lymphocyte Count
Stable or Increasing
Decreasing

139 (68.1)
65 (31.9)

132 (60.0)
88 (40.0)

271 (63.9)
153 (36.1)

HIV RNA Response***
Stable or Declining
Increasing

162 (79.4)
42 (20.6)

(45.9)
(54.1)

263 (62.0)
161 (38.0)

Adherence Measures

101
119

Note. ***p<.001

Summary
Bivariate and descriptive analyses related to the study groups and covariates have
been presented. Several statistically significant differences between the SAI and usual
care group have been reported.
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Bivariate Analyses and Logistic Regression
The following section will describe the bivariate analyses and logistic regression
associated with the study. Initially a series of Chi-Square analyses were conducted to
investigate the relationship between adherence outcomes (self-reported and pharmacy
refill), treatment response (CD4 lymphocyte and HIV RNA), treatment conditions (SAI
and usual care) and the covariates in the study. Variables found to be independently
associated with adherence or treatment response at a significance level of p = .10 or less
were considered for inclusion in a regression model.
Logistic regression was performed on each outcome variable (self-reported
adherence, pharmacy refill adherence, CD4 lymphocyte response and HIV RNA
response) to test the effects of the treatment condition while controlling for potentially
confounding effects (adherence services and intervention, HIV disease specific factors,
ARV specific factors and sociodemographic factors).
All models were checked for high intercorrelation using collinearity diagnostics
within SPSS. Tolerance values were satisfactory with no evidence of intercorrelation
between covariates. Singularity was assessed using SPSS. Variance inflation factor
values were all greater than 10 suggesting no evidence of singularity. Omnibus tests of
model coefficients were performed on each of the models and values <.05 were obtained.
These findings suggest acceptable goodness of fit for the models. Hosmer and
Lemeshow tests were performed for each of the models and values >.05 were calculated.
These findings also suggest support of the models.
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Study Aim One: Adherence Outcomes
The purpose of the first study aim was to determine whether patients participating
in the SAI program experienced higher levels of adherence compared to patients
receiving usual care, controlling for adherence services and intervention, HIV diseasespecific factors, ARV-specific factors, and sociodemographic factors. Two hypotheses
were tested:
1)

Patients participating in the SAI program will have higher levels of selfreported adherence compared to patients receiving usual care, controlling
for selected covariates.

2)

Patients participating in the SAI program will have higher levels of
pharmacy refill adherence compared to patients receiving usual care,
controlling for selected covariates.

Self-Reported Adherence
Bivariate analyses were calculated on self-reported adherence and each of the
covariates and the treatment condition. The data are displayed in Tables 22 and 23.
There were several significant findings. Approximately 65% of patients who had health
insurance self-reported adherence rates of at least 90% while a higher percentage (81.7%)
of subjects without insurance self-reported adherence levels > 90%. Individuals who
reported acquisition of HIV infection associated with intravenous drug use (IDU) route
had lower self-reported medication adherence while the men who have sex with men
(MSM) group reported higher levels. A higher percentage of subjects that did not have a
history of active substance abuse (91.2%) self-reported adherence levels > 90% compared
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to those with active substance abuse (81.7%). Finally, subjects with a history of mental
health disorders self-reported a higher percentage of medication adherence below the
acceptable rate of 90%. Lastly, subjects participating in the SAI were more likely to
report adherence levels > 90%.

Table 22
Bivariate Analysis - Self-Reported Adherence: Sociodemographic and HIV Disease Specific
Factors
Self-Reported Adherence
Covariates

> 90%

n

(%)

< 90%

n

(%)

Pearson
Chi-Square
(significance level .10 or less)

Sociodemographic Covariates
Age (years)
19-29
30-39
40-49
50-59
> 60
Gender
Male
Female
Race
White
Black
Other
Ethnicity
Non-Hispanic
Hispanic
Income (% Federal Poverty Level)
<100 %
101-200 %
> 200 %
Housing Status
Permanent
Nonpermanent
Health Insurance
Yes
No

28
83
149
86
18

(7.7)
(22.8)
(40.9)
(23.6)
(4.9)

3
11
29
12
5

(5.0)
(18.3)
(48.3)
(20)
(8.3)

259
105

(71.2)
(28.8)

40
20

(66.7)
(33.3)

199
159
6

(54.7)
(43.7)
(1.6)

30
27
3

(50.0)
(45.0)
(5.0)

268
96

(73.6)
(26.4)

41
19

(68.3)
(31.7)

244
90
30

(67.0)
(24.7)
(8.2)

48
41
1

(80.0)
(18.3)
(1.7)

359
5

(98.6)
(1.4)

57
3

(95.0)
(5.0)

239
125

(65.7)
(34.3)

49
11

(81.7)
(18.3)
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6.059, df 1, p=.014

Table 22 continued
Bivariate Analysis - Self-Reported Adherence: Sociodemographic and HIV Disease Specific
Factors
Self-Reported Adherence
Covariates

> 90%

n
HIV Disease Specific Covariates
HIV Risk Factor
MSM
Heterosexual
IDU
Other
Disease Stage
HIV (non-AIDS)
AIDS

Years Living with HIV
<5
6-10
11-15
>15
Active Substance Abuse
Yes
No
Mental Health Disorder
Yes
No

(%)

< 90%

n

(%)

Pearson
Chi-Square
(significance level .10 or less)

132
197
26
9

(36.3)
(54.1)
(7.1)
(2.5)

14
36
10
0

(23.3)
(60.0)
(16.7)
(0)

138
226

(37.9)
(62.1)

17
43

(28.3)
(71.7)

149
109
69
37

(40.9)
(29.9)
(19.0)
(10.2)

28
19
8
5

(46.7)
(31.7)
(13.3)
(8.3)

32
332

(8.8)
(91.2)

11
49

(18.3)
(81.7)

5.147, df 1, p=.023

96
268

(26.4)
(73.6)

23
37

(38.3)
(61.7)

3.649, df 1, p=.056
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9.811, df 3, p=.020

Table 23
Bivariate Analysis- Self-Reported Adherence: ARV and Adherence Counseling and
Intervention Specific Factors
Self-Reported
Adherence
> 90%
< 90%

Covariates

n

(%)

ARV Specific Covariates
Dosing Frequency
Once Daily
113 (31.0)
Twice Daily
251 (69.0)
Type of ARV Regimen
Protease Inhibitor
199 (54.7)
NNRTI
145 (39.8)
Triple NRTI
20 (5.5)
Daily ARV Pill Burden
151 (41.5)
2-4
174 (47.8)
5-8
39 (10.7)
9-15
Adherence Counseling and Intervention
Received Adherence
Counseling
24 (6.6)
Yes
340 (93.4)
No
No. of Counseling Sessions
340 (93.4)
0
18 (4.9)
1
2 (0.5)
2
2 (0.5)
3
4
1 (0.3)
>5
1 (0.3)
Adherence Counseling
(minutes)
0
30-60
61-120
>120
Adherence Aids Prescribed
Yes
No
Treatment Condition
SAI
Usual Care

n

(%)
19
41

(31.7)
(68.3)

36
20
4

(60.0)
(33.3)
(6.7)

22
30
8

(36.7)
(50.0)
(13.3)

7
53

(11.7)
(88.3)

53
5
2
0
0
0

(88.3)
(8.3)
(3.3)
(0)
(0)
(0)

340
7
13
4

(96.4)
(1.9)
(3.6)
(1.1)

53
1
3
3

(88.3)
(1.7)
(5.0)
(5.0)

13
351

(3.6)
(96.4)

3
57

(5.0)
(95.0)

191
173

(52.5)
(47.45)

13
47

(21.7)
(78.3)
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Pearson
Chi-Square
(significance level .10 or less)

19.581, df 1, p<.0005

The initial factors included in the logistic regression included income, housing
status, health insurance, HIV risk factor, active substance abuse, mental health disorder
and treatment condition. Through an iterative process factors that did not make
significant contributions in the regression were removed and regression was repeated
with the remaining factors. Factors were reinserted if the model was negatively affected
by the removal of a covariate. Covariates selectively removed from the regression
included income, health insurance, HIV risk factor, and mental health disorder. Housing
status was removed because a small sample size related to nonpermanently housed
subjects created unstable results.
After adjusting for covariates, subjects in the SAI group remained significantly
more likely to self-report medication adherence > 90% as compared to the usual care
group (adjusted OR = 3.944; 95% CI 2.058, 7.557; p < 0.0005). Additionally, patients
with a history of substance abuse were less likely to report favorable medication
adherence (OR 2.237; CI 1.033, 4.864; p=.041). Approximately 68% of all cases were
explained by this regression model (c-statistic 0.677). Based on the logistic regression
results, the null hypothesis of no difference in self-reported adherence between the two
groups was rejected. Patients who participated in the SAI program were almost four
times more likely to report adherence levels > 90%. These results are presented in Table
24.
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Table 24
Logistic Regression Analysis: Summary of Predictors of Self-Reported Adherence (> 90%)
Odds
Ratio

95%
Confidence
Interval

Wald
ChiSquare

P

β

Treatment Condition

1.372

3.944

2.058, 7.557

17.017

<.0005

History of Substance Use

-0.805

2.237

1.033, 4.864

4.167

0.041

Variable

Note. Overall model, Chi-Square = 24.566, df=2, p <.0005.

Pharmacy Refill Adherence
Bivariate analyses were calculated on pharmacy refill adherence and each of the
covariates and the treatment condition. The data are displayed in Table 25. There were
several significant findings. In most of the age groups, similar percentages of subjects
had both favorable (> 90%) and unfavorable (<90%) pharmacy refill adherence.
However, nearly twice as many subjects in the age range of 30-39 years had unfavorable
pharmacy refill adherence (29.4%) while only 15.5% of subjects had favorable
adherence. An inverse relationship was seen in the age group of 50-59 years: nearly
double the percentage of subjects demonstrated favorable adherence (29.1%) while
16.7% had unfavorable levels. These differences were significant (Chi-Square 17.287, df
4, p=.002). White patients also had a higher percentage of favorable pharmacy refill
adherence.
A higher percentage of subjects with household income <100% of Federal
Poverty Level demonstrated lower adherence levels (76% compared with 62.3%) while
those with income levels between 101-200% had nearly twice the rate of favorable
pharmacy refill adherence at a level > 90% (29.5% compared to 17.6%). A greater
percentage of subjects without health insurance (38.2%) demonstrated pharmacy refill
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adherence > 90% compared with insured patients (25.5%) (Chi-Square 7.862, df 1,
p=.005). Of subjects reporting active substance use, almost twice as many demonstrated
pharmacy refill adherence <90% (13.2%) compared to those with favorable refill
adherence (7.3%).

Table 25
Bivariate Analysis- Pharmacy Refill Adherence: Sociodemographic and HIV Disease
Specific Factors
Pharmacy Refill Adherence
Pearson
> 90%
< 90%
Covariates
Chi-Square
n=204

n
Sociodemographic Covariates
Age (years)
18-29
30-39
40-49
50-59
> 60
Gender
Male
Female
Race
White
Black
Other
Ethnicity
Non-Hispanic
Hispanic
Income (% Federal Poverty Level)
<100 %
101-200 %
> 200 %
Housing Status
Permanent
Nonpermanent
Health Insurance
Yes
No

(%)

n=220

n

(%)

14
34
95
64
13

(6.4)
(15.5)
(43.2)
(29.1)
(5.9)

17
60
83
34
10

(8.3)
(29.4)
(40.7)
(16.7)
(4.9)

160
60

(72.7)
(27.3)

139
65

(68.1)
(31.9)

137
77
6

(62.3)
(35.0)
(2.7)

92
109
3

(45.1)
(53.4)
(1.5)

155
65

(70.5)
(29.5)

154
50

(75.5)
(24.5)

137
65
18

(62.3)
(29.5)
(8.2)

155
36
13

(76.0)
(17.6)
(6.4)

215
5

(97.7)
(2.3)

201
3

(98.5)
(1.5)

136
84

(61.8)
(38.2)

152
52

(74.5)
(25.5)
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(significance level .10 or less)

17.287, df 4, p=.002

14.765, df 2, p=.001

9.653, df 2, p=.008

7.862, df 1, p=.005

Table 25 continued
Bivariate Analysis- Pharmacy Refill Adherence: Sociodemographic and HIV Disease
Specific Factors
Pharmacy Refill Adherence
Pearson
>
90%
<
90%
Covariates
Chi-Square
n=204

n

(%)

HIV Disease Specific Factors covariates
HIV Risk Factor
MSM
88 (40.0)
Heterosexual
111 (50.5)
IDU
18 (8.2)
Other
3 (1.4)
Disease Stage
HIV (non-AIDS)
90 (40.9)
AIDS
130 (50.1)
Years Living with HIV
<5
96 (43.6)
6-10
73 (33.2)
11-15
32 (14.5)
>15
19 (8.6)
Active Substance Abuse
Yes
16 (7.3)
No
204 (92.7)
Mental Health Disorder
Yes
63 (52.9)
No
157 (51.5)

n=220

n

(%)

58
122
18
6

(28.4)
(59.8)
(8.8)
(2.9)

65
139

(31.9)
(68.1)

81
55
45
23

(39.7)
(27.0)
(21.1)
(11.3)

27
177

(13.2)
(86.8)

56
148

(47.1)
(48.5)

(significance level .10 or less)

7.09, df 3, p=.069

3.735, df 1, p=.053

4.129, df 1, p=.042

There were no significant differences between pharmacy refill adherence and
ARV characteristics and adherence counseling and intervention specific factors. Lastly, a
higher percentage (54.5%) of subjects participating in the SAI had pharmacy refill
adherence > 90% compared to those receiving usual care (45.5%) (Chi-square 0.578, df 1,
p=.008). These data are displayed in Table 26.
The initial factors included in the logistic regression for pharmacy refill adherence
included age, race, income, health insurance, HIV risk factor, disease stage, active
substance abuse, time associated with adherence counseling and treatment condition.
Factors that did not have significant contributions in the regression were removed
including time associated with adherence counseling, and active substance abuse. Health
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insurance was removed as it was believed that this factor and the treatment condition of
SAI explained the same information.
Table 26
Bivariate Analysis - Pharmacy Refill Adherence: ARV and Adherence Counseling and
Intervention Specific Factors
Covariates

Pharmacy Refill Adherence
> 90%
< 90%

n

ARV Covariates
Dosing Frequency
65
Once Daily
155
Twice Daily
Type of ARV Regimen
Protease Inhibitor
115
NNRTI
92
Triple NRTI
13
Daily ARV Pill Burden
95
2-4
5-8
104
9-15
21
Adherence Services and Intervention
Received Adherence
Counseling
Yes
12
208
No
No. of Counseling Sessions
208
0
1
10
2
2
3
0
4
0
>5
0
Adherence Counseling
(minutes)
208
0
30-60
2
61-120
9
>120
1
Adherence Aids Prescribed
Yes
6
No
214
Treatment Condition
SAI
120
Usual Care
100

(%)

n

(%)

(29.5)
(70.5)

67
137

(32.8)
(67.2)

(52.3)
(41.8)
(5.9)

120
73
11

(58.8)
(35.8)
(5.4)

(43.2)
(47.3)
(9.5)

78
100
26

(38.2)
(49.0)
(12.7)

(5.5)
(94.5)

19
185

(9.3)
(90.7)

(94.5)
(4.5)
(0.9)
(0)
(0)
(0)

185
13
2
2
1
1

(90.7)
(6.4)
(1.0)
(1.0)
(0.5)
(0.5)

(94.5)
(0.9)
(4.1)
(0.5)

185
6
7
6

(90.7)
(2.9)
(3.4)
(2.9)

(2.7)
(97.3)

10
194

(4.9)
(95.1)

(54.5)
(45.5)

84
120

(41.2)
(58.8)
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Pearson
Chi-Square
(significance level .10 or less)

7.578, df 1, p=.006

After adjusting for covariates, subjects in the SAI group remained significantly
more likely to achieve 90% or more pharmacy refill adherence compared to the usual
care group (OR 1.833, CI 1.206, 2.788; p=.005). In this regression, age was treated as a
continuous variable. For every increase in year of age, there was approximately a 5%
increase in the likelihood of having a favorable pharmacy refill adherence outcome.
White race had a negative association with pharmacy refill adherence (OR 0.496; CI
.039, 0.749; p=.001). Approximately 68% of all cases were correctly predicted by this
regression model (c-statistic 0.683). Based on the logistic regression results, the null
hypothesis for hypothesis number two was rejected. These results are presented in Table
27.

Table 27
Logistic Regression Analysis: Summary of Predictors of Pharmacy Refill Adherence
β

Odds
Ratio

95%
Confidence
Interval

Wald
ChiSquare

P

Variable
Treatment Condition

0.606

1.833

1.206 – 2.788

8.038

0.005

Age

0.049

1.050

1.026 – 1.074

17.633

<.0005

Race

-0.701

0.496

0.329 – 0.749

11.150

0.001

Note. Overall model, Chi-Square = 43.012, df=5, p < .0005.
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Study Aim One: Summary
The two hypotheses associated with the first study aim were supported. Logistic
regression analyses support significant differences in self-reported adherence and pharmacy
refill adherence associated with participation in the SAI program.
Study Aim Two: Treatment Response Outcomes
The purpose of the second study aim was to determine whether patients participating
in the SAI program experience improved response to treatment compared to patients
receiving usual care, controlling for HIV disease-specific factors, ARV-specific factors, and
sociodemographic factors. Two hypotheses were tested:
1) Patients participating in the SAI program will have better immunologic (CD4
lymphocyte) responses to HAART compared to patients receiving usual care,
controlling for selected covariates.
2) Patients participating in the SAI program will have better virologic (HIV RNA)
responses compared to patients receiving usual care, controlling for selected
covariates.
CD4 Lymphocyte Response
There were few statistically significant findings in the bivariate analyses of CD4
lymphocyte response and each of the covariates and the treatment condition. Overall,
approximately 64% of subjects in this study demonstrated an unfavorable declining CD4
lymphocyte response. Although the difference is not significant, a larger percentage of
subjects identifying as Hispanic had a declining CD4 response (57.4% compared with 33.7%
for non-Hispanic) (Chi-square 2.912, df 1, p=.088). All 8 of the subjects with nonpermanent housing demonstrated a stable or increasing CD4 response (Chi square 3.147, df 1,
p=.076, Yates’ Correction for Continuity). This information is displayed in Table 28.

105

Table 28
Bivariate Analysis - CD4 Lymphocyte Response: Sociodemographic and HIV Disease
Specific Factors
CD4 Lymphocyte
Pearson
Declining
Stable/Increasing
Covariates
Chi-Square
N

Sociodemographic Covariates
Age (years)
19-29
30-39
40-49
50-59
> 60
Gender
Male
Female
Race
White
Black
Other
Ethnicity
Non-Hispanic
Hispanic
Income
(% Federal Poverty Level)
<100 %
101-200 %
> 200 %
Housing Status
Nonpermanent
Permanent
Health Insurance
Yes
No
HIV Disease Specific Factors
HIV Risk Factor
MSM
Heterosexual
IDU
Other
Disease Stage
HIV (non-AIDS)
AIDS
Years Living with HIV
<5
6-10
11-15
>15
Active Substance Abuse
Yes
No
Mental Health Disorder
Yes
No

(%)

n

(%)

13
35
58
36
11

(8.5)
(22.9)
(37.9)
(23.5)
(7.2)

18
59
120
62
12

(6.6)
(21.8
(44.3)
(22.9)
(4.4)

112
41

(73.2)
(26.8)

187
84

(69.0)
(31.0)

78
71
4

(51.0)
(46.4)
(2.6)

151
115
5

(55.7)
(42.4)
(1.8)

104
49

(68.0)
(32.0)

205
66

(75.6)
(24.4)

113
30
10

179
71
21

0
153

(73.9)
(19.6)
(6.5)
b
(0)
(100)

8
263

(66.1)
(26.2)
(7.7)
g
(3.0)
(97.0)

46
107

(30.1)
(69.9)

90
180

(33.2)
(66.8)

52
82
16
3

(34.0)
(53.6)
(10.5)
(2.0)

94
151
20
6

(34.7)
(55.7)
(7.4)
(2.2)

59
94

(38.6)
(61.4)

96
175

(35.4)
(64.6)

61
43
33
16

(39.9)
(28.1)
(21.6)
(10.5)

116
85
44
26

(42.8)
(31.4)
(16.2)
(9.6)

19
134

(12.4)
(87.6)

24
247

(8.9)
(91.9)

46
107

(30.1)
(69.9)

73
198

(26.9)
(73.1)
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(significance level .10 or less)

2.912, df 1 p=.088

3.147, df 1, p=.076
(Yates’ Correction for Continuity)

Of the 271 subjects with a favorable CD4 response, 34.3% received a once daily
regimen while 65.7% received a twice daily regimen (Chi-square 3.554, df 1, p=.059).
Immunologic response based on pill burden was similar when subjects received 2-4 or 58 pills per day. However, when daily pill burden exceeded 8 pills per day, there were a
higher percentage of subjects that had CD4 decline (Chi-square 8.719, df 2, p=.013).
Lastly, 68% of subjects in the SAI (n=139) had a favorable immunologic response
compared with only 60% of those in usual care (n=132) (Chi-square 3.039 df 1, p=.0816).
Table 29 depicts this information.

Table 29
Bivariate Analysis- CD4 Lymphocyte Response: ARV and Adherence Counseling and
Intervention Specific Factors
CD4 Lymphocyte
Pearson
Declining
Stable/Increasing
Covariates
Chi-Square
n

ARV Specific Covariates
Dosing Frequency
Once Daily
Twice Daily
Type of ARV Regimen
Protease Inhibitor
NNRTI
Triple NRTI
Daily ARV Pill Burden
2-4
5-8
9-15

(%)

n

(%)

(significance level .10 or less)

39
114

(25.5)
(74.5)

93
178

(34.3)
(65.7)

3.554, df 1, p=.059

89
56
8

(58.2)
(36.6)
(5.2)

146
109
16

(53.0)
(40.2)
(5.9)

56
71
26

(36.6)
(46.4)
(17.0)

117
133
21

(43.2)
(49.1)
(7.7)
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8.719, df 2, p=.013

Table 29 continued
Bivariate Analysis- CD4 Lymphocyte Response: ARV and Adherence Counseling and
Intervention Specific Factors
CD4 Lymphocyte
Pearson
Declining
Stable/Increasing
Covariates
Chi-Square
n

Adherence Services and Intervention
Received Adherence
Counseling
Yes
10
No
143
No. of Counseling Sessions
0
143
1
10
0
2
0
3
0
4
0
>5
Adherence Counseling
(minutes)
0
143
5
30-60
4
61-120
1
>120
Adherence Aids Prescribed
Yes
3
No
150
Treatment Condition
SAI
65
Usual Care
88

(%)

n

(%)

(6.5)
(93.5)

21
250

(7.7)
(92.3)

(93.5)
(6.5)
(0)
(0)
(0)
(0)

250
13
4
2
1
1

(92.3)
(4.8)
(150)
(0.7)
(0.6)
(0.6)

(93.5)
(3.3)
(2.6)
(0.7)

250
3
12
6

(92.3)
(1.1)
(4.4)
(2.2)

(2.0)
(98.0)

13
258

(4.8)
(95.2)

(42.5)
(57.5)

139
132

(51.3)
(48.7)

(significance level .10 or less)

3.039 df 1, p=.0816

The initial factors included in the regression for CD4 lymphocyte response
included ethnicity, housing status, ARV dosing, ARV daily pill burden, and treatment
condition. Factors that did not have significant contributions in the regression were
removed (housing status and ARV dosing) and regression was repeated with the
remaining factors. The only significant finding in this regression was related to daily pill
burden. Subjects receiving 2-4 tablets per day were less likely to achieve a favorable
CD4 lymphocyte response (OR 0.917; CI 0.844, 0.996; p=.039). Approximately 59% of
all cases were correctly predicted by this regression model (c-statistic 0.594). Based on
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logistic regression analysis, the null hypothesis for the third research question was
supported as no significant relationship was identified between the SAI program and CD4
lymphocyte response. These results are presented in Table 30.

Table 30
Logistic Regression Analysis: Summary of Predictors of CD4 Lymphocyte Response
Odds
Ratio

95%
Confidence
Interval

Wald
ChiSquare

P

β

Ethnicity

0.392

1.480

0.949 – 2.306

2.996

0.083

Daily Pill Burden

-.087

0.917

0.844 – 0.996

4.287

0.039

Treatment Condition

0.338

1.402

0.935 – 2.102

2.670

0.102

Variable

Note. Overall model, Chi-Square = 10.535, df=3, p = .015.

HIV RNA Response
There were a number of statistically significant findings in the bivariate analyses
of HIV RNA response, the covariates and the treatment condition. The
sociodemographic and HIV disease specific data are displayed in Table 31.
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Table 31
Bivariate Analysis- HIV RNA Response: Sociodemographic and HIV Disease Specific
Factors
HIV RNA Response
Pearson
Increasing
Stable/Decreasing
Covariates
Chi-Square
n

Sociodemographic Covariates
Age (years)
19-29
30-39
40-49
50-59
> 60
Gender
Male
Female
Race
White
Black
Other
Ethnicity
Non-Hispanic
Hispanic
Income
(% Federal Poverty
Level)
<100 %
101-200 %
> 200 %
Housing Status
Permanent
Nonpermanent
Health Insurance
Yes
No
HIV Disease Specific Covariates
HIV Risk Factor
MSM
Heterosexual
IDU
Other
Disease Stage
HIV (non-AIDS)
AIDS
Years Living with HIV
<5
6-10
11-15
>15
Active Substance Abuse
Yes
No
Mental Health Disorder
Yes
No

(%)

n

(%)

9
32
74
34
12

(5.6)
(19.9)
(46.0)
(21.1)
(7.5)

22
62
104
64
11

(8.4)
(23.6
(39.5)
(24.3)
(4.2)

113
48

(70.2)
(29.8)

186
77

(70.7)
(29.3)

74
83
4

(46.0)
(51.6)
(2.5)

155
103
5

(58.9)
(39.2)
(1.9)

122
39

(75.8)
(24.2)

187
76

(71.1)
(28.9)

117
28
6

(72.7)
(23.6)
(3.7)

175
63
25

(66.5)
(24.0)
(9.5)

157
4

(97.5)
(2.5)

259
4

(98.5)
(1.5)

135
26

(83.9)
(16.1)

153
110

(58.2)
(41.8)

53
88
15
5

(32.9)
(54.7)
(9.3)
(3.4)

93
145
21
4

(35.4
(55.1)
(8.0)
(1.5)

50
111

(31.1)
(68.9)

105
158

(39.9)
(60.1)

62
52
32
15

(38.5)
(32.3)
(19.9)
(9.3)

115
76
45
27

(43.7)
(28.9)
(17.1)
(10.3

19
142

(11.8)
(88.2)

24
239

(9.1)
(90.9)

47
114

(29.2)
(70.8)

72
191

(27.4)
(72.6
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(significance level .10 or less)

6.766, df 2, p=.034

5.112, df 2, p=.078

30.218, df 1 p<.0005

3.386, df 1, p=.066

Bivariate analysis suggested there were racial differences related to virologic
response. A higher percentage of white patients achieved or sustained a virologic
response (58.9%) compared to blacks (39.2%) (Chi-square 6.766, df 2, p=.034). A
higher percentage of subjects in the lowest income group experienced increasing HIV
RNA while a greater percentage of patients at the highest income level of >200% FPL
had a favorable virologic response (Chi-square 5.112, df 2, p=.078).
Sixty-two percent of all subjects had a favorable virologic response (n=263). Of
these, 58.2% had insurance, 41.8% did not. Of the 161 subjects that had unfavorable
virologic responses, 16.1% did not have insurance while 83.9% did have insurance (Chi
square 30.218, df 1 p<.0005).
Almost two-thirds of the patients had a diagnosis of AIDS. Of patients with an
unfavorable HIV RNA response, 68.9% had an AIDS diagnosis. Of the 163 subjects that
had a favorable HIV RNA response, 60.1% had an AIDS diagnosis.
Although few patients received adherence aids (n=16), 87.5% of them were
prescribed to subjects that demonstrated stable or declining HIV RNA (Chi-square 4.58,
df 1, p=.032). Lastly, 61.6% of subjects participating in the SAI demonstrated favorable
virologic responses compared to 38.4% of those in usual care (Chi-square 50.442, df 1,
p<.0005). This data is presented in Table 32.
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Table 32
Bivariate Analysis- HIV RNA Response: ARV and Adherence Counseling and
Intervention Specific Factors
CD4 Lymphocyte
Covariates

Declining
n
(%)

ARV Specific Covariates
Dosing Frequency
Once Daily
49
Twice Daily
112
Type of ARV Regimen
Protease Inhibitor
89
NNRTI
65
Triple NRTI
7
Daily ARV Pill Burden
61
2-4
76
5-8
24
9-15
Adherence Services and Intervention
Received Adherence
Counseling
Yes
8
153
No
No. of Counseling Sessions
153
0
8
1
0
2
0
3
0
4
0
>5
Adherence Counseling
(minutes)
153
0
4
30-60
61-120
4
>120
0
Adherence Aids Prescribed
Yes
2
No
159
Treatment Condition
SAI
42
Usual Care
119

Stable/Increasing
n
(%))

Pearson
Chi-Square
(significance level .10 or less)

(30.4)
(69.6)

83
180

(31.6)
(68.4)

(55.3)
(40.4)
(9.1)

146
100
17

(55.5)
(38.0)
(6.5)

(37.9)
(47.2)
(14.9)

112
128
23

(42.6)
(48.7)
(8.7)

(5.0)
(95.0)

23
240

(8.7)
(91.3)

(95.0)
(5.0)
(0)
(0)
(0)
(0)

240
15
4
2
1
1

(91.3)
(5.7)
(1.5)
(0.8)
(0.4)
(0.4)

(95.0)
(2.5)
(2.5)
(0)

240
4
12
7

(91.3)
(1.5)
(4.6)
(2.7)

(1.2)
(98.8)

14
249

(5.3)
(94.7)

4.58, df 1, p=.032

(26.1)
(73.9)

162
101

(61.6)
(38.4)

50.442, df 1, p<.0005

The initial factors included in the regression for HIV RNA response included
race, income, health insurance, HIV disease stage, adherence aids prescribed and
treatment condition. Factors that did not have significant contributions in the regression
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were removed (race, health insurance and income) and regression was repeated with the
remaining factors. After adjusting for covariates, subjects who participated in the SAI
program were over four and a half times more likely to achieve a favorable virologic
response (OR 4.573; CI 2.953, 7.080; p<.0005). Subjects who received an adherence aid
were almost seven times more likely to achieve a favorable VL response (OR 6.87; CI
1.473, 32.072; p=.014). Approximately 73% of all cases were correctly predicted by this
regression model (c-statistic 0.725). Based on this logistic regression, the null hypothesis
of no differences in virologic response between the SAI and usual care group for
hypothesis number four was rejected. These results are presented in Table 33.

Table 33
Logistic Regression Analysis: Summary of Predictors of HIV RNA Response
Variable

β

Odds
Ratio

95%
Confidence
Interval

Wald
ChiSquare

p

Treatment Condition

1.520

4.573

2.953 - 7.080

46.411

<.0005

Race

0.465

1.592

1.039 - 2.438

4.564

0.033

Adherence Aids

1.928

6.873

1.473 - 32.072

6.015

0.014

Note. Overall model, Chi-Square = 63.999, df=3, p <.0005.

Study Aim Two: Summary
The first hypothesis associated with study aim two was rejected as there were no
significant differences in CD4 lymphocyte response between the SAI and usual care
group. The second hypotheses was supported as logistic regression analyses
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demonstrated significant differences in HIV RNA response associated with the SAI
program.
Summary
This chapter has presented the statistical analyses for the investigation.
Demographic results were presented first, followed by the results of bivariate analyses
between the adherence outcomes, treatment outcomes, treatment groups and covariates.
Finally, the results of the logistic regression for each study aim were presented. Three
hypotheses were supported; one was rejected. In the concluding chapter, these results will
be discussed along with a discussion of the implications for future research and nursing
practice.
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CHAPTER 5: DISCUSSSION, CONCLUSIONS AND RECOMMENDATIONS
Introduction
This final chapter presents a synthesis of the research results with a discussion of
the findings, conclusions, study limitations and implications for clinical practice.
Recommendations for dissemination of the findings and for future research are proposed.
Summary of the Study
The purpose of this retrospective comparative study was to better understand the
effects of an existing antiretroviral access program on adherence to HAART and response
to treatment compared to patients enrolled in usual care. In the structured adherence
intervention (SAI) staff closely monitored monthly HIV medication refills and provided
structured adherence interventions when indicated. Patients receiving usual care were
enrolled in a Medicaid-funded medication access program and did not receive ongoing
medication refill monitoring and structured adherence intervention. Both patient groups
received their ARV medications and outpatient HIV medical care from a single treatment
center and pharmacy.
The study included 424 subjects comparably distributed between the usual care
and SAI group. Bivariate analyses were used to identify significant associations between
the usual care and SAI group regarding sociodemographic characteristics, HIV disease
related factors, ARV-related characteristics and utilization of adherence services and
intervention. Logistic regression was performed to identify predictors of self-reported
medication adherence, pharmacy refill adherence, CD4 lymphocyte response and HIV
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RNA response. This research provided valuable information related to antiretroviral
adherence and treatment outcomes for patients participating in usual care and a statebased antiretroviral access program. The study is unique in that no known investigations
have previously tested a structured programmatic intervention on ARV adherence and
HIV treatment outcomes.
Discussion and Conclusions
The following is a discussion of the findings according to the study aims and
research questions in the study along with the conclusions that may be drawn from this
research study.
Study Aim One
The first study aim was to determine whether patients participating in the SAI
program experienced higher levels of adherence compared to patients receiving usual
care, controlling for adherence services and intervention, HIV disease-specific factors,
ARV-specific factors, and sociodemographic factors. To answer the first research
question, “Is there a difference in self-reported adherence in subjects participating in the
SAI program compared to those who receive usual care?,” logistic regression was
performed to test the null hypotheses that there were no differences between self-reported
adherence between participants in the usual care group of subjects and the subjects
participating in the SAI. After controlling for covariates, subjects in the SAI group were
significantly more likely to self-report medication adherence > 90% as compared to the
usual care group (OR = 3.944; 95% CI 2.058, 7.557; p < 0.0005) and the null hypothesis
was rejected.
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To answer the second research question, “Is there a difference in pharmacy refill
adherence in subjects participating in the SAI program compared to those who receive
usual care?,” logistic regression was performed to test the null hypothesis that there were
no differences between pharmacy refill adherence between participants in the usual care
group of subjects and the subjects participating in the SAI. After adjusting for covariates,
subjects in the SAI group remained significantly more likely to achieve 90% or more
pharmacy refill adherence compared to the usual care group (OR 1.833, 95% CI 1.206,
2.788; p=.005). The null hypothesis was rejected.
Several unexpected findings were seen in this study including low overall
utilization of the adherence specialist and comparable use of the adherence specialist
between the two study groups. The majority of the study population (92.7%) did not
receive any adherence counseling or intervention (n=393) from the adherence specialist.
A total of only 31 subjects (7.3%) received at least one face-to-face counseling session
with the adherence specialist. The range of counseling time was 30-360 minutes with a
mean of 91 minutes during the 6 month study period. Fewer than 4% of all patients
received adherence aids such as pill boxes, customized medication schedules, and alarm
watches (n=16) from the adherence specialist.
There are several potential explanations for the unexpected low utilization of the
adherence specialist’s services. Primary healthcare providers (PCPs) delivering
outpatient care services to the subjects may have provided adherence interventions on
their own without initiating formal consultation with the adherence specialist. Similarly,
PCPs may have initiated the use of pill boxes and may have developed detailed written
medication schedules without the involvement and knowledge of the adherence
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specialist. If these interventions were provided by the PCP, they would not have been
captured by the databases used in this study. Patients may also have received adherence
education and counseling services from community case management organizations that
receive Ryan White Grant funding specifically for these purposes. Similarly, these
interventions could not have been measured and included in this study.
Based on the embedded procedural and administrative processes associated with
the ADAP, it seemed likely that clients in this program would demonstrate greater
utilization of adherence services and intervention then the usual care group. In this study,
utilization of adherence services between the two groups was comparable. It is possible
that PCPs and other staff were accustomed to providing adherence support to patients in
the SAI group and consequently extended these interventions to all patients as a
component of routine care. Healthcare providers may have had little knowledge of the
patients’ method of medication access and consequently delivered comparable services to
all patients within the normal course of health care delivery.
Surprisingly, there were no significant differences in pharmacy refill adherence,
self-reported adherence, and HIV RNA response related to ARV pill burden. While the
literature supports improved adherence with lower pill burden, this study showed
comparable adherence and treatment outcomes regardless of ARV pill burden. The
largest percentage of subjects (48.1%) had a pill burden of 5-8 ARV pills per day while
only 11.1% had daily pill burden of 9-15 and 43.2% received 2-4 per day. Although
immunologic response based on pill burden was similar whether subjects received 2-4 or
5-8 pills per day, a higher percentage of subjects experienced CD4 decline when daily
pill burden exceeded 8 pills (Chi-square 8.719, df 2, p=.013).
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Pill burden for treatment of other health disorders such as diabetes, psychiatric
conditions, cardiovascular and metabolic disorders was not assessed in this study. It is
possible that HAART bill burden was minimal compared to pill burden associated with
the treatment of other health conditions. Measurement of overall pill burden may better
explain any potential differences in adherence and treatment outcomes.
Study Aim Two
The second study aim was to determine whether patients participating in the SAI
program experienced improved response to treatment compared to patients receiving
usual care, controlling for HIV disease-specific factors, ARV-specific factors, and sociodemographic factors.
To answer the first research question, “Is there a difference in CD4 lymphocyte
response in subjects participating in the SAI program compared to those who receive
usual care?” logistic regression was performed to test the null hypotheses that there were
no differences between CD4 lymphocyte response in the usual care group of subjects and
the subjects participating in the SAI. After controlling for covariates, there were no
significant differences between the two groups and the null hypothesis was supported
(OR 1.402; CI: 1.402,2.102; p = 0.102).
This unexpected finding may be explained by several factors. Most notably,
expected CD4 lymphocyte response occurs more slowly compared to HIV RNA response
which occurs more rapidly when initiating ARV therapy (Bartlett & Gallant, 2005;
Nieuwkerk & Oort, 2005). It is likely that a six-month observation period may have been
inadequate to fully appreciate the immunologic response to therapy. CD4 lymphocytes
are also affected by diurnal and seasonal variations. Some clinicians prefer to monitor
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the percentage of CD4 lymphocytes rather than the absolute number (Bartlett & Gallant,
2005), but not all laboratories provide this additional measurement. Unfortunately CD4
percentages were not available in this study. The subjects in this study also included a
broad mix of clients at all ranges of HIV disease. Patients starting initial therapy would
be expected to have a robust CD4 lymphocyte response while it would be unlikely for
those chronically infected and on long-term therapy to experience a significant response.
Lastly, the sample size was lower than expected and there may not have been enough
power associated with this sample size to detect a small change in the CD4 lymphocyte
response.
To answer the final research question, “Is there a difference in HIV RNA
response in subjects participating in the SAI program compared to those who receive
usual care?” logistic regression was performed to test the null hypotheses that there were
no differences in the HIV RNA response between the two groups. After controlling for
covariates, subjects who participated in the SAI program were over four and a half times
more likely to achieve a favorable virologic response (OR 4.573; 95% CI 2.953, 7.080;
p<.0005). There was a statistically significant difference between the two groups and the
null hypothesis of no difference between the groups was rejected.
Limitations of the Study
There are several limitations to consider in this study. Each of these will be
reviewed in the following section.
The sample was biased because all subjects were already enrolled in an AIDS
drug assistance program and they all received care from one outpatient clinic.
Additionally, all subjects received medication from one pharmacy. Clinical, pharmacy
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and medication access programs were all at the same site. As a result, the findings may
not be representative of the true population in the state-wide ADAP. The sample did
represent racial and ethnic diversity consistent with HIV-infected patients within the local
community.
Another source of bias is related to self-reported measurement of adherence.
Although self-report is one of the most common methods of assessing medication
adherence, inaccuracy may result due to imprecise or inconsistent questioning, patient
forgetfulness and poor recall, or the patient’s desire to provide socially desirable
responses along with a desire to please the healthcare provider and prevent criticism.
Consequently, when self-reporting methods are used to assess adherence, levels are
frequently over-estimated.
The retrospective research design was purposely selected to minimize several
possible confounders that existed in the years 2006 and 2007. Medicare D prescription
drug plans were initiated in January 2006. Clients experienced unique barriers to
medication access, unexpected loss of previous healthcare benefits and interruptions in
their supply of medication. While most of the Medicare D complications resolved by
2007, eligibility requirements for Florida ADAP and other local funding plans occurred
in 2007, once again disrupting the normal operations of ADAP.
A priori power estimates suggested a minimum sample size of 678 subjects were
required for power of 0.80. A large number of potential subjects were unexpectedly
excluded from analysis because they did not use the on-site pharmacy. Consequently,
this study is inadequately powered to detect the effect size specified in the research
design.
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The findings of this research may not be generalizable to other populations. The
sample of the participants may not reflect the overall population of those with HIV since
the study site was a public clinic frequently used by those who are indigent or have public
insurance such as Medicare or Medicaid. Patients with commercial insurance tend to
seek private practices for their HIV care, so those employed in jobs that provide
insurance were underrepresented in this sample, as well as those with high income.
These findings cannot be applied to populations that were not represented in the subject
groups. Further studies are recommended across various geographic areas, ethnic areas
and other clinical settings.
Although this study examined a number of covariates, it is possible that there are
unknown or additional variables that might impact adherence and treatment outcomes in
this population. Examples might include level of education, social support, quality of
life, number of previous antiretroviral regimens, presence of ARV resistance, and
participation in a clinical drug study. Adherence education and counseling provided by
case managers in the community may also have an effect on pharmacy refill adherence,
self-reported adherence and treatment outcomes.
The short time of follow-up may have limited the ability to measure the longrange effect of the SAI. Although the relatively short follow-up time in this study may be
inadequate to fully appreciate the virologic and immunologic response to therapy,
extending the study period might result in additional confounders. For example, the
population utilizing this public clinic is often transient, incarcerated and often lost to
follow-up.
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This study examined multiple variables that could impact both treatment response
and adherence. It is difficult to attribute the true effect of each variable. Future study
using path analysis might elucidate the true effect of each covariate.
Three types of antiretroviral therapy were considered in this study: (1) nonnucleoside reverse transcriptase based; (2) protease inhibitor based; and (3) triple
nucleoside reverse transcriptase based. The protease inhibitor (PI) ritonavir is frequently
administered in a low-dose along with a primary PI as a pharmacokinetic booster to the
primary PI. Boosting a PI with ritonavir increases drug exposure and prolongs the
plasma half-life of the primary protease inhibitor. This allows for reduced dosing
frequency and pill burden and may improve overall adherence to the regimen (National
Institutes of Health, 2006). Ritonavir-boosting was not assessed in this study and may
be an important characteristic to assess in future studies since boosting can improve
adherence through reduced pill burden and greater drug exposure could result in
improved virologic and immunologic treatment response outcomes. Nelfinavir is the
only protease inhibitor that cannot be effectively boosted by ritonavir (Bartlett & Gallant,
2005). Since a number of subjects received nelfinavir as a component of HAART, it may
be helpful to study both boosted and unboosted PI-based regimens.
This study included patients who only used one consistent pharmacy to obtain
their medication. A large number of patients (n=569) used alternative pharmacies
throughout the community. Although the demographic characteristics of this population
are similar to the sample of patients in the usual care group, the pharmacy refill
adherence rates are not known. Future studies should consider investigating the
pharmacy refill rates at community pharmacies to investigate whether there are any
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unique features from the on-site pharmacy compared to community pharmacies. Since
the dedicated on-site pharmacy is used to providing adherence messages within general
conversation with patients, it is theoretically possible that even this communication may
have an effect on patient adherence to medication therapy. It is not known what type of
adherence messages or encouragement is provided by community pharmacies.
There was little effect on adherence related to active substance abuse and mental
health disorders despite literature which supports a negative impact on adherence. The
lack of effect in this study may be related to the coding of the substance abuse and mental
health diagnoses or the small sample size. The covariates related to mental health and
substance abuse were based on healthcare provider coding and documentation in the
medical record. There were no clearly defined objective or operational definitions related
to these diagnoses. It is possible that these diagnoses were under-diagnosed, overdiagnosed or misdiagnosed.
Significance
This study demonstrates a significant effect on self-reported adherence, pharmacy
refill adherence, and HIV RNA response associated with participation in the AIDS drug
assistance program. There are potential unknown covariates that may be involved with
adherence and future qualitative inquiry may be helpful in identifying them and their
potential effect on adherence. This will be discussed in another section.
Funding for AIDS Drug Assistance Programs is provided by the federal
government and often supplemented with individual state funds. With limited national
and state funding for these programs, it is imperative that funds be used as effectively as
possible to serve the greatest number of clients possible and to produce the most optimal
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clinical outcomes. This study demonstrates significant improvement in medication
adherence as well as treatment outcomes associated with participation in one ADAP and
can serve as a model to local, regional and national programs as a potential means to
optimize medication adherence and treatment response with limited resources.
In the State of Florida, a centralized database contains administrative and clinical
data related to each ADAP participant including CD4 lymphocyte counts, HIV RNA
results, antiretroviral specific information and sociodemographic information. The
findings from this study can serve as a starting point for program administrators to
analyze statewide data to identify treatment response rates and program effectiveness.
Additionally, administrators could utilize this database to identify problematic areas or
areas that may need additional resources based on observation of clinical outcomes as
measured by CD4 lymphocyte and HIV RNA response.
Ongoing discussion is occurring on a national level related to the collection and
study of clinical outcome data from the various AIDS Drug Assistance Programs within
the United States. This study demonstrates the potential benefit from examining these
types of data and the potential benefits for program administrators, clinicians and
patients.
Components of the structured adherence program may be appropriate for settings
with limited technology or limited resources. Closely monitoring pharmacy refills and
proactively implementing communication with patients before they run out of medication
may be quite appropriate for rural or even sites in the developing world in an effort to
improve adherence and treatment outcomes.
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This study contributes to our knowledge of the difficulties in fully understanding
the patient-level determinants of ARV medication adherence. There are numerous
variables that affect adherence and ongoing research is indicated to continue to increase
our understanding of this complex process. Results of this study provide a foundation for
future research exploring issues of medication adherence, pharmacy refill adherence, and
participation in structured medication access program.
It is important that the findings from this study are communicated to local staff
involved in the study as well as the administrators at the regional, state and national level.
The findings clearly support better adherence and clinical outcomes in the population
participating in the medication access program. By disseminating this information to
clinicians and administrators, others may be encouraged to implement similar procedures
for monitoring pharmacy refills and initiating structured treatment intervention. With
hundreds of medication access programs across the United States, it is important for
clinicians and administrators to recognize the potential impact of their programs on
adherence and treatment response.
Several immediate plans are in process to disseminate the findings of this study.
Locally, the staff associated with the study site will be informed of the findings. On a
community level, attendees at the local Association of Nurses in AIDS Care meeting will
be provided with an overview of the study and its findings. At a regional level, the study
results will be presented to a coalition of government representatives, corporations and
community advocates representing fourteen southern states and their respective ADAPs.
Lastly, the study will be submitted for publication in peer-reviewed journal.
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Implications for Nursing Practice
The findings of this study support the ability of a structured adherence
intervention within a medication access program to effectively influence clinical
outcomes and adherence associated with the treatment of HIV-infected patients. Nurses
and other healthcare providers play a key role in providing ongoing education related to
ARV medication including proper administration, management of medication side
effects, adherence to therapy, and adherence to clinical care. Nurses are in a key role to
formally and informally assess adherence and to refer patients for specialized adherence
education and counseling as needed. Nurses often have more contact with the patient
than any other member of the health care team and are in a pivotal position to assess
adherence and implement creative strategies to improve adherence and increase
knowledge.
Nurses should have strong interviewing skills to be able to elicit information
regarding adherence in a professional and nonjudgmental manner. Nurses are in a key
role to recognize nonadherence and initiate appropriate adherence interventions as
quickly and effectively as possible.
Nurse practitioners (NPs) continue to serve as primary care providers for many
patients with HIV infection and are instrumental in initiating and managing antiretroviral
therapy. By providing thorough patient education, selection of tolerable agents that the
patient is able to adhere to, and prompt referral to adherence specialists, NPs can
influence adherence in a positive and proactive manner. Nurse researchers are active in
adherence research and continue to contribute to this growing body of knowledge.
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There continues to be an ongoing need to develop effective adherence
interventions and to increase awareness related to the importance of medication
adherence among patients living with HIV disease. It is important to find adherence
interventions that are cost-effective and replicable outside of a research setting.
It is equally important to encourage ongoing educational activities for patients,
nurses, and other health care providers to increase their knowledge and awareness related
to medication adherence and pharmacy refill adherence as a means to improve
immunologic and virologic success with HAART.
There is a growing need for effective patient education regarding readiness for
treatment, HIV illness management, drug-drug interactions, potential drug side effects
and side effect management. The complexity of treatment and the side effects of
treatment make this an important area for nursing practice. Similarly, there is a need for
further development of a standardized definition of adherence and valid objective
measures of adherence that are appropriate for both clinical research and clinical care
settings. Future research needs to address the best method to assess adherence to ensure
reliability and validity, since this is the crucial outcome measure in all adherence research
and because adherence has a direct impact on patient morbidity and mortality. The selfreport method of measuring adherence may not be the most useful predictor of adherence.
Recommendations for Future Study
Based upon the review of related studies and the findings from this study, a
number of recommendations are made for future research in this area. This study could
be replicated using a prospective design with a larger sample size that encompasses
different geographic areas and which follows subjects for a longer time period. This
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would generate findings that would be more representative of the population with HIV
and AIDS and would have the power to more accurately measure the effects of covariates
associated with adherence and treatment response. It would be helpful to measure HIV
RNA response and CD4 count response as a continuous variable over many months to
many years. Inclusion of CD4 lymphocyte percentage may be an additional variable to
consider in the study. A longitudinal study design might permit longer follow-up to
determine if adherence and treatment outcome responses are retained for long periods of
time.
Future studies should consider distinguishing between ritonavir boosted protease
inhibitor based regimens and non-ritonavir boosted PI regimens. Although non-boosted
PI regimens are becoming less common, there were a significant amount of nelfinavir
based regimens in the study (non-boosted). Non-boosted PI regimens are traditionally
less potent and durable that boosted-PIs and may have less favorable treatment outcomes.
While this study defined three types of antiretroviral therapy regimens (non-nucleoside
reverse transcriptase based, protease inhibitor based, and triple nucleoside reverse
transcriptase based), future studies should consider incorporating newer regimens that
emerged in 2007 and 2008 including entry inhibitor based, integrase inhibitor based, and
second generation NNRTI-based.
A qualitative research component would be very useful in future research.
Qualitative inquiry may help to identify perceptions and behaviors associated with the
SAI, other adherence strategies used by patients (such as cellular phone alarms, internet
based systems, and other personal strategies), factors identified by the clinical population
to be important in their adherence to medications, and the burden of chronic disease.
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Qualitative inquiry involving staff of both the medication access program and pharmacy
may also generate findings that influence adherence such as adherence messages
delivered within the normal course of business communication, informal teaching
messages, and other verbal and nonverbal messages.
Ongoing research in this field should include the study of clients that use
community pharmacies as well as those that use pharmacies that deliver monthly
medications directly to patients’ homes. General community pharmacies (as opposed to
community HIV-specialty pharmacies) may not be as knowledgeable about HIV
treatment agents and may not understand the importance of high levels of adherence to
medication refills. More pharmacies are offering free home delivery of HIV medications
as a means to increase their business while providing a valuable service and convenience
to patients. The adherence implications of these services have not been formally studied
and published.
It is also important to consider the effect of community-based adherence
educators on patient adherence and treatment outcomes. Although these programs are
often funded by Ryan White Grant funding, they frequently operate with case
management and social work agencies with little or no contact with medical care
providers, AIDS drug assistance programs, and client pharmacies. Qualitative studies of
these programs may provide important information that impact clinical care and
pharmacy refill behaviors. As the population affected by HIV continues to impact more
people of color and more minorities, it is important to consider the potential impact of
cultural barriers and language barriers of subjects whose primary language is nonEnglish.
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While the findings of this study demonstrate improved adherence and treatment
response associate with the ADAP, it would be beneficial to investigate the costs
associated with the program and determine if the program is indeed cost-effective for the
adherence and outcome benefits associated with the program. With dwindling federal
and state funding of these programs, this information is critical in ensuring ongoing
funding of these valuable programs.
Summary
The purpose of this retrospective comparative study was to better understand the
effects of an existing antiretroviral access program on adherence to HAART and response
to treatment compared to usual care. In the structured adherence intervention (SAI)
providers closely monitored monthly HIV medication refills and provided structured
adherence intervention when indicated. Patients receiving usual care were enrolled in a
Medicaid-funded medication access program and did not receive ongoing medication
refill monitoring and structured adherence intervention. Both patient groups received
their ARV medications and outpatient HIV medical care from a single treatment center
and pharmacy
Three of the four hypotheses were confirmed in this study. Patients participating
in the SAI demonstrated higher levels of both self-reported and pharmacy refill adherence
compared to patients receiving usual care. Patients in the SAI were almost four times
more likely to self-report > 90% adherence (OR 3.94, p<.0005) compared to the usual
care group and almost twice as likely to achieve favorable pharmacy refill adherence (OR
1.83, p=.005).

Although patients participating in the SAI program demonstrated better

virologic (HIV RNA) responses to HAART compared to patients receiving usual care,
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immunologic (CD4 lymphocyte) responses to HAART were not significantly different
compared to subjects in the usual care program. Patients in the SAI were more than four
times as likely to achieve a favorable HIV RNA response compared to those in the SAI
(OR=4.57, p<.0005).
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